US6437131B1 - Process for preparing imidazoquinolinamines - Google Patents

Process for preparing imidazoquinolinamines Download PDF

Info

Publication number
US6437131B1
US6437131B1 US09/678,192 US67819200A US6437131B1 US 6437131 B1 US6437131 B1 US 6437131B1 US 67819200 A US67819200 A US 67819200A US 6437131 B1 US6437131 B1 US 6437131B1
Authority
US
United States
Prior art keywords
substituted
carbon atoms
imidazo
quinolin
tetrazolo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime, expires
Application number
US09/678,192
Inventor
John F. Gerster
Kyle J. Lindstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medicis Pharmaceutical Corp
Original Assignee
3M Innovative Properties Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 3M Innovative Properties Co filed Critical 3M Innovative Properties Co
Assigned to 3M INNOVATIVE PROPERTIES COMPANY reassignment 3M INNOVATIVE PROPERTIES COMPANY ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MINNESOTA MINING AND MANUFACTURING, A CORPORATION OF DELAWARE
Priority to US09/678,192 priority Critical patent/US6437131B1/en
Priority to US10/180,678 priority patent/US6534654B2/en
Publication of US6437131B1 publication Critical patent/US6437131B1/en
Application granted granted Critical
Priority to US10/352,606 priority patent/US6613902B2/en
Priority to US10/360,210 priority patent/US6624305B2/en
Priority to US10/624,014 priority patent/US6897314B2/en
Priority to US10/974,258 priority patent/US7026482B2/en
Assigned to GRACEWAY PHARMACEUTICALS, LLC reassignment GRACEWAY PHARMACEUTICALS, LLC ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: 3M INNOVATIVE PROPERTIES COMPANY
Assigned to BANK OF AMERICA, N.A., AS FIRST LIEN COLLATERAL AGENT reassignment BANK OF AMERICA, N.A., AS FIRST LIEN COLLATERAL AGENT FIRST LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS Assignors: CHESTER VALLEY PHARMACEUTICALS, LLC, GRACEWAY PHARMACEUTICALS, LLC
Assigned to BANK OF AMERICA, N.A., AS SECOND LIEN COLLATERAL AGENT reassignment BANK OF AMERICA, N.A., AS SECOND LIEN COLLATERAL AGENT SECOND LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS Assignors: CHESTER VALLEY PHARMACEUTICALS, LLC, GRACEWAY PHARMACEUTICALS, LLC
Assigned to GRACEWAY PHARMACEUTICALS, LLC, CHESTER VALLEY PHARMACEUTICALS, LLC reassignment GRACEWAY PHARMACEUTICALS, LLC RELEASE OF FIRST LIEN SECURITY AGREEMENT IN PATENTS Assignors: BANK OF AMERICA, N.A.
Assigned to CHESTER VALLEY PHARMACEUTICALS, LLC, GRACEWAY PHARMACEUTICALS, LLC reassignment CHESTER VALLEY PHARMACEUTICALS, LLC RELEASE OF SECOND LIEN SECURITY AGREEMENT IN PATENTS Assignors: BANK OF AMERICA, N.A.
Assigned to BANK OF AMERICA, N.A., AS FIRST LIEN COLLATERAL AGENT reassignment BANK OF AMERICA, N.A., AS FIRST LIEN COLLATERAL AGENT FIRST LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS Assignors: CHESTER VALLEY PHARMACEUTICALS, LLC, GRACEWAY PHARMACEUTICALS, LLC
Assigned to DEUTSCHE BANK TRUST COMPANY AMERICAS, AS SECOND LIEN COLLATERAL AGENT reassignment DEUTSCHE BANK TRUST COMPANY AMERICAS, AS SECOND LIEN COLLATERAL AGENT SECOND LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS Assignors: CHESTER VALLEY PHARMACEUTICALS, LLC, GRACEWAY PHARMACEUTICALS, LLC
Assigned to MEDICIS PHARMACEUTICAL CORPORATION reassignment MEDICIS PHARMACEUTICAL CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRACEWAY PHARMACEUTICALS, LLC
Assigned to GOLDMAN SACHS LENDING PARTNERS LLC reassignment GOLDMAN SACHS LENDING PARTNERS LLC SECURITY AGREEMENT Assignors: MEDICIS PHARMACEUTICAL CORPORATION
Assigned to BARCLAYS BANK PLC, AS SUCCESSOR AGENT reassignment BARCLAYS BANK PLC, AS SUCCESSOR AGENT NOTICE OF SUCCESSION OF AGENCY Assignors: GOLDMAN SACHS LENDING PARTNERS, LLC
Adjusted expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Definitions

  • This invention relates to processes for preparing 1H-imidazo[4,5-c]quinolin-4-amines and to intermediates for use in preparing 1H-imidazo[4,5-c]quinolin-4-amines.
  • 5,395,937 discloses a process involving amination of the 4-position of a 3-nitroquinoline-2,4-disulfonate with a substituted amine.
  • Tile final step of the process involves hydrogenolysis to provide the 4-amino compound.
  • This invention provides a process for preparing a 1H-imidazo[4,5-c]quinolin-4-amine comprising the steps of:
  • step (ii) nitrating the compound from step (i) to provide a 4-nitrotetrazolo[1,5-a]quinolin-5-ol;
  • step (iii) sulfonylating the compound from step (ii) to provide a 4-nitrotetrazolo[1,5-a]quinolin-5-sulfonate;
  • step (iv) reacting the compound from step (iii) with an amine to provide a (5-substituted)-4-nitrotetrazolo[1,5-a]quinolin-5-amine;
  • step (v) reducing the compound from step (iv) to provide a (5-substituted)tetrazolo[1,5-a]quinolin-4,5-diamine;
  • step (vi) reacting the compound from step (v) with a carboxylic acid or an equivalent thereof to provide a (5-substituted) (6-substituted) 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline;
  • step (vii) reacting the compound from step (vi) with triphenylphosphine to provide a (1-substituted) (2-substituted) N-triphenylpliosphinyl-III-iinidazo[4,5-c]quinolin-4-amine;
  • step (viii) hydrolyzing the compound from step (vii) to provide a (1-substituted) (2-substituted) 1H-imidazo[4,5-c]quinolin-4-amine; and (xi) isolating the (1-substituted) (2-substituted) 1H-iniidazo[4,5-c]quinolin-4-amine or a pharmaceutically acceptable addition salt thereof.
  • This invention also provides a process for preparing a 1H-imidazo[4,5-]quinolin-4-amine comprising the steps of:
  • step (ii) reacting the compound from step (i) with sodium azide to provide (5-substituted)-4-nitrotetrazolo[1,5-a]quinolin-5-amine;
  • step (iii) reducing the compound from step (ii) to provide a (5-substituted)tetrazolo[1,5-a]quinolin-4,5-diamine;
  • step (iv) reacting the compound from step (iii) with a carboxylic acid or an equivalent thereof to provide a (5-substituted) (6-substituted) 6 H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline;
  • step (v) reacting the compound from step (iv) with triphenylphosphine to provide a (1-substituted) (2-substituted) N-triphenylphosphinyl- 1H-imidazo[4,5-c]quinolin-4-amine;
  • step (vi) hydrolyzing the compound from step (v) to provide a (1-substituted) (2-substituted) 1H-imidazo[4,5-c]quinolin-4-amine;
  • This invention also provides a process for preparing a 1H-imidazo[4,5-c]quinolin-4-amine comprising the steps of:
  • step (ii) reacting the compound from step (i) with hydrazine to provide a (1-substituted) (2-substituted) 4-hydrazino-1H-imidazo[4,5-c]quinoline;
  • step (iii) reacting the compound from step (ii) with sodium nitrite to provide a (5-substituted) (6-substituted) 6H-imidazo[4, 5 -c]tetrazolo[1,5-a]quinoline;
  • step (iv) reacting the compound from step (iii) with triphenylphosplhine to provide a (1-substituted) (1-substituted) N-triphenylphosphinyl-1H -imidazo[4,5-c]quinolin-4-amine;
  • step (v) hydrolyzing the compound from step (iv) to provide a (1-substituted) (2-substituted) 1H-imidazo[4,5-c]quinolin-4-amine;
  • This invention also provides processes involving certain of the various individual steps set forth above, and combinations of such steps.
  • this invention also provides 4-nitrotetrazolo[1,5-a]quinolin-5-ols, 4-nitrotetrazolo[1,5-a]quinoline-5-sulfonates, (5-substituted)-4-nitrotetrazolo[1,5-a]quinolin-5-amines, (5-substituted)tetrazolo[1,5-a]quinolin-4,5-diamines, (5-substituted) (6-substituted) 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinolines, (1-substituted) (2-substituted) 4-hydrazino- 1H-imidazo[4,5-c]quinolines, and (1-substituted) (2-substituted) (2-substituted) N-triphenylphosphinyl-1H-imidazo[4,5-c]quinolin-4-amines.
  • Substituents designated parenthetically herein indicate that the substituent is optionally present, e.g., a 4-(substituted) amino compound contains either an unsubstituted 4-amino group or a substituted 4-amino group.
  • Reaction Scheme I illustrates processes of the invention and the preparation of compounds of the invention.
  • the unsubstituted compound of Formula I is a known compound and other compounds of Formula I can be prepared by methods known to those skilled in the art and disclosed, e.g., in Chemistry of Heterocyclic Compounds (English Edition), 1981, 16, (12), 1286-1288 (Zyryanov).
  • a 4-nitrotetrazolo[1,5-a]quinolin-5-ol of Formula II is provided by nitrating a tetrazolo[1,5-a]quinolin-5-ol of Formula I.
  • Conventional conditions for such reactions are well known. Preferred conditions in the instance where R is hydrogen involve heating in acetic acid in the presence of nitric acid. Preferred conditions in other instances will depend upon the particular tetrazolo[1,5-a]quinolin-5-ol used, and those skilled in the art will be able to select suitable conditions.
  • the product can be isolated from the reaction mixture using conventional methods.
  • a 4-nitrotetraozolo[1,5-a]quinolin-5-sulfonate of Formula III is provided by reacting a 4-nitrotetrazolo[1,5-a]quinolin-5-ol of Formula II with a sulfonyl halide or preferably a sulfonic anhydride.
  • Suitable sulfonyl halides include alkylsulfonyl halides such as methanesulfonyl chloride and trifluoromethanesulfonyl chloride, and arylsulfonyl halides such as benzenesulfonyl chloride, p-bromobenzenesulfonyl chloride and p-toluenesulfonyl chloride.
  • Suitable sulfonic anhydrides include those corresponding to the above-mentioned sulfonyl halides.
  • Sulfonic anhydrides are preferred in view of the fact that the sulfonate anion generated as a by-product of the reaction is a relatively poor nucleophile and as such does not give rise to undesired side products such as those in which the nitro group is displaced.
  • a particularly preferred sulfonic anhydride is trifluoromethanesulfonic anhydride.
  • the reaction is preferably carried out by combining a compound of Formula II with a base, preferably an excess of a tertiary amine base (e.g., a trialkylamine base such as triethyl amine) in a suitable solvent such as dichloromethane and then adding the sulfonyl halide or sulfonic anhydride.
  • a base preferably an excess of a tertiary amine base (e.g., a trialkylamine base such as triethyl amine) in a suitable solvent such as dichloromethane and then adding the sulfonyl halide or sulfonic anhydride.
  • the addition is preferably carried out in a controlled fashion (e.g., dropwise) and at a reduced temperature (e.g., about 0 °C.).
  • the product can be isolated by conventional methods or it can be carried on without isolation as described below in connection with step (3).
  • a (5-substituted) 4-nitrotetrazolo[1,5-a]quinolin-5-amine of Formula IV is provided by reacting a 4-nitrotetrazolo[1,5-a]quinolin-5-sulfonate of Formula III with an amine, preferably in the presence of an excess of an amine base in a solvent such as dichloromethane.
  • Suitable amines include ammonia and preferably primary amines.
  • Primary amines provide 5-substituted amino compounds of Formula IV wherein the amino substituent is represented by R 1 .
  • Particularly preferred amines include isobutylamine and 2-aminomethyl-2-propanol.
  • the reaction can be carried out by adding an excess of amine to the reaction mixture resulting from Step (2).
  • the reaction can also be carried out by adding an excess of amine to a solution of the compound of Formula III in a solvent such as dichloromethane.
  • a solvent such as dichloromethane.
  • the reaction can be run at ambient temperature.
  • the product can be isolated from the reaction mixture using conventional methods.
  • a (5-substituted)tetrazolo[1,5-a]quinolin-4,5-diamine of Formula V is provided by reducing a (5-substituted) 4-nitrotetrazolo[1,5-a]quinolin-5-amine of Formula IV.
  • Methods for such reduction are well know to those skilled in the art.
  • the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon or palladium on carbon.
  • the reduction can be conveniently carried out on a Paar apparatus in a solvent such as ethanol.
  • the product can be isolated from the reaction mixture using conventional methods.
  • a (5-substituted) (6-substituted) 6H-10 imidazo[4,5-c]tetrazolo[1,5-a]quinoline of Formula VI is provided by reacting a (5-substituted)tetrazolo[1,5-a]quinolin-4,5-diamine of Formula V with a carboxylic acid or an equivalent thereof.
  • Suitable equivalents to carboxylic acid include acid halides, orthoesters, and 1,1-dialkoxyalkyl alkanoates.
  • the carboxylic acid or equivalent is selected such that it will give rise to the desired 6-substituent in the compound of Formula VI wherein the 6-substituent is designated R 2 (e.g., acetyl chloride will give rise to a compound where R 2 is methyl).
  • the reaction can be run in the absence of solvent or preferably in an inert solvent in the presence of a carboxylic acid or equivalent thereof with sufficient heating to drive off any alcohol or water formed as a side product of the reaction.
  • the product can be isolated from the reaction mixture using conventional methods.
  • a (1-substituted) (2-substituted) N-triphenylphosphinyl-1H-imidazo[4,5-c]quinolin-4-amine of Formula VII is provided by reacting a (5-substituted) (6-substituted) 61i-imidazo[4,5-c]tetrazolo[1,5-]quinoline of Formula VI with triphenylphosphine.
  • the reaction can be carried out by combining a compound of Formula VI with triphenylpliosphine in a suitable solvent such as 1,2-dichlorobenzene and heating.
  • the product can be isolated from the reaction mixture using conventional methods.
  • a (1-substituted) (2-substituted) 1H-imidazo[4,5-c]quinoline-4-amine of Formula VIII is provided by hydrolysis of a (1-substituted) (2-substituted) N-triphenylphosphinyl-1H-imidazo[4,5-c]quinolin-4-amine of Formula VII.
  • Such a reaction can be carried out by general methods well known to those skilled in the art (e.g., by heating in a lower alkanol in the presence of an acid).
  • the product can be isolated from the reaction mixture by conventional means.
  • R′ can be any group that can be incorporated into a sulfonyl halide or a sulfonic anhydride.
  • Alkyl e.g., methyl
  • haloalkyl including perfluoroalkyl e.g., trifluoromethyl
  • aryl e.g., phenyl, halophenyl and tolyl
  • Reaction Scheme II illustrates processes of the invention and the preparation of compounds of the invention.
  • Compounds of Formula IX and methods for their preparation are known and disclosed, e.g. in U.S. Pat. Nos. 4,988,815 (Andre), and 5,268,376 (Gerster), both patents being incorporated herein by reference.
  • step (1) of Reaction Scheme II a (5-substituted) 4-nitrotetrazolo[1,5-a]quinolin-5-amine of Formula IV is provided by reacting a (4-substituted) amino-2-chloro-3-nitroquinoline of Formula IX with sodium azide.
  • the reaction can be carried out by combining the compound of Formula IX with sodium azide in a suitable solvent such as N,N-dimethylformamide and heating (about 50° C.).
  • the product can be isolated from the reaction mixture using conventional methods.
  • Steps (2), (3), (4) and (5) of Reaction Scheme II can be carried out in the same manner as steps (4), (5), (6) and (7) of Reaction Scheme I respectively.
  • Reaction Scheme III illustrates processes of the invention and the preparation of compounds of the invention.
  • Compounds of Formula X and methods for their preparation are known and disclosed, e.g., in European Patent Application 90.301776.3, U.S. Pat. Nos. 4,689,338 (Gerster), 4,698,348 (Gerster), 4,929,625 (Gerster), 4,988,815 (Andre), 5,268,376 (Gerster), and 5,389,640 (Gerster) all six patents being incorporated herein by reference.
  • step (1) of Reaction Scheme III a (1-substituted) (2-substituted) 4-hydrazino-1H-imidazo[4,5-c]quinoline of Formula XI is provided by reacting a (1 substituted) (2-substituted) 4-chloro-1H-imidazo[4,5-c]quinoline of Formula X with hydrazine.
  • the reaction can be carried out by combining a compound of Formula X with an excess of hydrazine and heating if necessary.
  • the product can be isolated from the reaction mixture using conventional methods.
  • step (2) of Reaction Scheme III a (5-substituted) (6-substituted) 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline of Formula VI is provided by reacting a (1-substituted) (2-substituted) 4-hydrazino-1H-imidazo[4,5-c]quinoline of Formula XI with sodium nitrite.
  • the reaction can be carried out by combining the compound of Formula XI with sodium nitrite in a suitable solvent (e.g., water) in the presence of an acid (e.g., acetic acid).
  • a suitable solvent e.g., water
  • an acid e.g., acetic acid
  • Steps (3) and (4) of Reaction Scheme III can be carried out in the same manner as steps (6) and (7) of Reaction Scheme I respectively.
  • the compounds of Formula VIII can be used in the form of acid addition salts such as hydrochlorides, dihydrogen sulfates, trihydrogen phosphates, hydrogen nitrates, methane sulfonates and salts of other pharmaceutically acceptable acids.
  • Pharmaceutically acceptable acid addition salts of Formula VIII are generally prepared by reaction of the respective compound with an equimolar amount of a strong acid, preferably an inorganic acid such as hydrochloric, sulfuric or phosphoric acid or an organic acid such as methanesulfonic acid in a polar solvent. Isolation of the salt is facilitated by the addition of a solvent in which the salt is insoluble (e.g., diethyl ether).
  • Processes of the invention provide as a final product a 1H-imidazo[4,5-c]quinolin-4-amine, preferred embodiments of which can be represented by Formula VIII.
  • 1H -imidazo[4,5-c]quinolin-4-amine is a compound defined by one of Formulas XXI-XXV below:
  • R 11 is selected from the group consisting of alkyl, hydroxyalkyl, acyloxyalkyl, benzyl, (phenyl)ethyl and phenyl, said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms and halogen, with the proviso that if said benzene ring is substituted by two of said moieties, then said moieties together contain no more than 6 carbon atoms; acylaminoalkyl wherein the alkyl moiety contains two to four carbon atoms; disubstitute aminoalkyl wherein tile alkyl moiety contains two to four carbon atoms; morpholinoalkyl wherein the alkyl moiety contains two to four carbon atoms; R 21 is selected from the group consisting
  • R 12 is selected from the group consisting of straight chain or branched chain alkenyl containing 2 to about 10 carbon atoms and substituted straight chain or branched chain alkenyl containing 2 to about 10 carbon atoms, wherein the substituent is selected from the group consisting of straight chain or branched chain alkyl containing 1 to about 4 carbon atoms and cycloalkyl containing 3 to about 6 carbon atoms; and cycloalkyl containing 3 to about 6 carbon atoms substituted by straight chain or branched chain alkyl containing 1 to about 4 carbon atoms; and
  • R 22 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to about eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of straight chain or branched chain alkyl containing one to about four carbon atoms, straight chain or branched chain alkoxy containing one to about four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than 6 carbon atoms; and
  • each R B is independently selected from the group consisting of straight chain or branched chain alkoxy containing one to about four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to about four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said R B groups together contain no more than 6 carbon atoms;
  • R 23 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl of one to about eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of straight chain or branched chain alkyl of one to about four carbon atoms, straight chain or branched chain alkoxy of one to about four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than 6 carbon atoms; and
  • each R C is independently selected from the group consisting of straight chain or branched chain alkoxy of one to about four carbon atoms, halogen, and straight chain or branched chain alkyl of one to about four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said R C groups together contain no more than 6 carbon atoms;
  • R 14 is —CH x R y
  • R y is hydrogen or a carbon-carbon bond, with the proviso that when R y is hydrogen R x is alkoxy of one to about four carbon atoms, hydroxyalkoxy of one to about four carbon atoms, 1-alkynyl of two to about ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when R y is a carbon-carbon bond R y and R x together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to about four carbon atoms;
  • R 24 is selected from the group consisting of hydrogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen; and
  • R D is selected from the group consisting of hydrogen, straight chain or branched chain alkoxy containing one to about four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to about four carbon atoms;
  • R 15 is selected from the group consisting of: hydrogen; straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; hydroxyalkyl of one
  • R S and R T are independently selected from the group consisting of rogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen;
  • X is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, haloalkyl of one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to about four carbon atoms, azido, alkylthio of one to about four carbon atoms; and
  • R E is selected from the group consisting of hydrogen, straight chain or branched chain alkoxy containing one to about four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to about four carbon atoms;
  • n can be zero, one, or two, n is preferably zero or one.
  • R A -R E are species embraced by It.
  • the preferred R substituent is hydrogen.
  • R 11 -R 15 are species embraced by R 1 .
  • the preferred R 1 substituents are alkyl of one to about six carbon atoms, hydroxy alkyl wherein the alkyl moiety contains one to about 6 carbon atoms, and arylalkyl wherein the alkyl moiety contains one to about three carbon atoms. Most preferably the R 1 substituent is 2-methylpropyl, 2-hydroxy-2-methylpropyl, benzyl or phenylethyl.
  • R 21 -R 25 are species embraced by R 2
  • the preferred R 2 substituents are hydrogen, alkyl of one to about four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, hydroxyl alkyl wherein the alkyl moiety contains one to about four carbon atoms, haloalkyl wherein the alkyl moiety contains one to about four carbon atoms, and aryloxymethyl.
  • the R 2 substituent is hydrogen, methyl, ethoxymethyl, or benzyl.
  • R substituents, R 1 substituents, and R 2 substituents will be incompatible with the particular reaction conditions described above in connection with the Reaction Schemes. Those skilled in the art, however, will be able to select alternative conditions under which the several steps can be carried out and/or methods of functional group protection and manipulation that will allow the use of the processes of the invention in the preparation of 1H-imidazo[4,5-c]quinolin-4-amines of diverse structures.
  • the crude 2-methyl-4-oxo-3,1-benzoxazine was dissolved in acetic acid (1.9 L).
  • Sodium azide 130.0 g was added to the solution in portions with stirring.
  • the reaction mixture was cooled in an ice bath to maintain the reaction temperature at 25 to 30° C. during the addition.
  • the reaction mixture was allowed to stir at ambient temperature over the weekend.
  • the acetic acid was removed under vacuum to provide a white solid.
  • the solid was combined with 10% sodium hydroxide (1.4 L) then heated on a steam bath for 1 hour. Additional sodium hydroxide (120 g of 50% sodium hydroxide) was added. The mixture was heated on a steam bath for an additional hour then allowed to cool to ambient temperature overnight.
  • Tetrazolo[1,5-a]quinolin-5-ol (10 g, 54 mmole, Example 1) was suspended in acetic acid (200 mL) then warmed to 40° C. Nitric acid (4 mL of 16M, 59 mmole) was added to the reaction mixture. The reaction mixture was heated at 80° C. for 30 minutes then allowed to cool to ambient temperature. The resulting precipitate was isolated by filtration, rinsed with water then recrystallized from isopropanol/water to provide 8.1 g of 4-nitrotetrazolo[1,5-a]quinolin-5-ol hydrate as light yellow plates, m.p. 186.5-187° C. Analysis: Calculated for C 9 H 5 N 5 O 3 . H 2 O: %C, 43.38; %H, 2.83; %N, 28.10; Found: %C, 43.27; %H, 2.84; %N, 28.25.
  • Acetyl chloride (16 g, 0.020 mole) was added dropwise to a solution of[(4-amino-5-tetrazolo[1,5-c]quinolinyl)amino]-2-methyl-2-propanol (5 g, 0.18 mole, Example 4) in acetonitrile.
  • the reaction mixture was stirred at ambient temperature for 4 hours.
  • the resulting precipitate was isolated by filtration then dissolved in acetic acid (about 50 mL). This solution was refluxed for 2 hours then neutralized with carbonate.
  • Triphenylphosphine (4.5 g, 17.0 mmole) was added to a mixture of ⁇ , ⁇ -dimethyl-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline-6-ethanol (2.4 g, 8:5 mmole, Example 9) and 1,2-dichlorobenzene.
  • the reaction mixture was heated at reflux for 3 hrs then concentrated under vacuum.
  • the residue was combined with methanol (400 mL) and hydrochloric acid (50 mL of 0.5N) then heated on a steam bath for 2 hours.
  • the resulting precipitate was isolated by filtration then washed with ether.
  • the solid was dissolved in water and the solution was made basic with 10% sodium hydroxide.
  • Aqueous sodium hydroxide (30 g of 50%) was added to a suspension of 2-methyl-[(4-nitro-5-tetrazolo[1,5-a]quinolinyl)amino]-2-propanol (34.0 g, 0.1125 mole, Example 3) in water (500 mL). The mixture was heated on a steam bath and the solid dissolved rapidly. The solution was heated for about 30 minutes and then upon stirring a solid began to precipitate. The mixture was made acidic with 6N hydrochloric acid. The resulting solid was isolated by filtration; washed in succession with water, ethanol and ether; then dried under vacuum at 100 °C. to provide 23.2 g of crude product as a pale yellow/green solid.
  • Triethylamine (0.6 mL, 4.32 mmole) was added to a suspension of 4-nitrotetrazolo[1,5-a]quinolin-5-ol (1.0 g, 4.32 mmoles, Example 2) in dicliloromethane (20 mL). The reaction mixture was cooled to 0° C. Trifle anhydride (0.73 mL, 4.32 mmole) was added. The reaction mixture was stirred for 3 hours at 0° C. The reaction mixture was diluted with dichloromethane (50 mL), washed with 0.5 N hydrochloric acid, dried over magnesium sulfate and concentrated under vacuum. The residue was combined with liexanes (100 mL), refluxed for 15 minutes and filtered.
  • N-(2-Methylpropyl)-4-nitrotetrazolo[1,5,-a]quinolin-5-amine (1.0 g, 3.5 mmole, Example 15), ethanol (100 mL) and Pt/C were placed in a Paar apparatus. The mixture was hydrogenated at 50 psi (3.44 ⁇ 10 5 Pa). The reaction mixture was filtered to remove the catalyst then concentrated under vacuum. The residue was recrystallized from ethyl acetate to provide 0.35 g of N 5 -(2-methylpropyl)tetrazolo[1,5-a]quinoline-4,5-diamine as off white needles, m.p. 148-150° C. Analysis: Calculated for C 13 H 16 N 6 : %C, 60.92; %H, 6.29; %N, 32.79; Found: %C, 60.94; %H, 6.25; %N, 32.93.
  • N 5 -(2-Methylpropyl)tetrazolo[1,5-a]quinoline-4,5-diamine (0.2 g, 0.78 mmole, Example 16) was combined with dietlioxyrnethlyl acetate (2 mL) and heated on a steam bath for 3 hours. Water (10 mL) and 10% sodium hydroxide (2 mL) were added and the reaction mixture was heated on a steam bath for 1 hour. A solid was isolated by filtration then recrystallized from methanol/ethyl acetate to provide 0.16 g of 6-(2-methylpropyl)-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline as a white crystalline solid, m.p.
  • Triethylamine (6 mL), 4-nitrotetrazolo[1,5-a]quinolin-5-ol (8.7 g, 37.6 mmole, Example 13) and dichloromethane (100 mL) were combined and stirred at ambient temperature until a solution was obtained. The solution was cooled to ⁇ 115° C. Trifle anhydride (6.5 mL) was added in portions to the cooled solution. The reaction mixture was allowed to warm to ambient temperature then filtered through a layer of silica gel. The filtrate was washed with cold dilute hydrochloric acid then dried over magnesium sulfate.
  • Triethylamine (5.25 mL) was added to the dichloromethane solution and the resulting mixture was stirred for about 10 minutes.
  • tert-Butylamine (4.2 mL) was added dropwise to the reaction mixture.
  • the reaction mixture was heated on a steam bath for about 15 minutes.
  • the resulting solid was isolated by filtration then purified by silica gel chromatography to provide the crude product as a yellow solid.
  • This material was recrystallized from ethanollwater to provide 5 g of N-(1,1-dimethyletliyl)-4-nitrotetrazolo[1,5-a]quinolin-5-amine.
  • the structure was confirmed by nuclear magnetic resonance spectroscopy.
  • N-(1,1-dimethylethyl)-4-nitrotetrazolo[1,5-a]quinolin-5-amine (4.2 g, Example 18), ethanol (100 mL) and Pt/C (0.5 g) were placed in a Paar apparatus. The mixture was hydrogenated. The reaction mixture was filtered to remove catalyst then concentrated to dryness under vacuum. The residue was recrystallized from ethyl acetate/dichloromethane to provide N 5 -(1,1-dimethylethyl)tetrazolo[1,5-a]quinoline-4,5-diamine as a pale blue crystalline solid.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

A process for preparing 1H-imidazo[4,5-c]quinolin-4-amines is disclosed. The process involves reacting a 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline with triphenylphosphine and hydrolyzing the product thereof

Description

This is a divisional of application Ser. No. 09/375,587 filed Aug. 17, 1999, now U.S. Pat. No. 6,150,523, which is a divisional of application Ser. No. 09/061,401 filed Apr. 16, 1998, now U.S. Pat. No. 5,998,619, which is a continuation of application Ser. No. 08/673,712 filed Jun. 21, 1996, now U.S. Pat. No. 5,741,908.
BACKGROUND OF THE INVENTION
1. Technical Field
This invention relates to processes for preparing 1H-imidazo[4,5-c]quinolin-4-amines and to intermediates for use in preparing 1H-imidazo[4,5-c]quinolin-4-amines.
2. Description of the Related Art
Certain antiviral immunomodulator 1H-imidazo[4,5-c]quinolin4-amines and methods for their preparation are known and disclosed. For example U.S. Pat. Nos. 4,689,338 and 4,929,624 (Gerster) disclose a method involving the step of heating the corresponding 4-chloro compound in the presence of ammonium hydroxide or ammonia under pressure to provide the 4-amino compound. U.S. Pat. No. 4,988,815 (Andre) discloses a process involving amination of the 4-position of a 3-nitro-1,4-dichloroquinoline. This process too involves as a final step the reaction of ammonia with a 4-chloro-1H-imidazo[4,5-c]quinoline.
Milder methods have been used in order to introduce the 4-amino group of 1H-imidazo[4,5-c]quinolin-4-amines. U.S. Pat. No. 5,175,296 (Gerster) discloses a process involving the reaction of a 1H-imidazo[4,5-c]quinoline 5N-oxide with an organic isocyanate and hydrolyzing the product to provide the 4-amino compound. U.S. Pat. No. 5,367,076 (Gerster) discloses a process involving the reaction of a 1H-1-imidazo[4,5-c]quinoline 5N-oxide with an acylating agent and reacting the product with an aminating agent to provide the 4-amino compound. U.S. Pat. No. 5,395,937 (Nikolaides) discloses a process involving amination of the 4-position of a 3-nitroquinoline-2,4-disulfonate with a substituted amine. Tile final step of the process involves hydrogenolysis to provide the 4-amino compound.
SUMMARY OF THE INVENTION
This invention provides a process for preparing a 1H-imidazo[4,5-c]quinolin-4-amine comprising the steps of:
(i) providing a tetrazolo[1,5-a]quinolin-5-ol;
(ii) nitrating the compound from step (i) to provide a 4-nitrotetrazolo[1,5-a]quinolin-5-ol;
(iii) sulfonylating the compound from step (ii) to provide a 4-nitrotetrazolo[1,5-a]quinolin-5-sulfonate;
(iv) reacting the compound from step (iii) with an amine to provide a (5-substituted)-4-nitrotetrazolo[1,5-a]quinolin-5-amine;
(v) reducing the compound from step (iv) to provide a (5-substituted)tetrazolo[1,5-a]quinolin-4,5-diamine;
(vi) reacting the compound from step (v) with a carboxylic acid or an equivalent thereof to provide a (5-substituted) (6-substituted) 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline;
(vii) reacting the compound from step (vi) with triphenylphosphine to provide a (1-substituted) (2-substituted) N-triphenylpliosphinyl-III-iinidazo[4,5-c]quinolin-4-amine;
(viii) hydrolyzing the compound from step (vii) to provide a (1-substituted) (2-substituted) 1H-imidazo[4,5-c]quinolin-4-amine; and (xi) isolating the (1-substituted) (2-substituted) 1H-iniidazo[4,5-c]quinolin-4-amine or a pharmaceutically acceptable addition salt thereof.
This invention also provides a process for preparing a 1H-imidazo[4,5-]quinolin-4-amine comprising the steps of:
(i) providing a (4-substituted) amino-2-chloro-3-nitroquinoline;
(ii) reacting the compound from step (i) with sodium azide to provide (5-substituted)-4-nitrotetrazolo[1,5-a]quinolin-5-amine;
(iii) reducing the compound from step (ii) to provide a (5-substituted)tetrazolo[1,5-a]quinolin-4,5-diamine;
(iv) reacting the compound from step (iii) with a carboxylic acid or an equivalent thereof to provide a (5-substituted) (6-substituted) 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline;
(v) reacting the compound from step (iv) with triphenylphosphine to provide a (1-substituted) (2-substituted) N-triphenylphosphinyl- 1H-imidazo[4,5-c]quinolin-4-amine;
(vi) hydrolyzing the compound from step (v) to provide a (1-substituted) (2-substituted) 1H-imidazo[4,5-c]quinolin-4-amine; and
(vii) isolating the (1-substituted) (2-substituted) 1H-imidazo[4,5-c]quinolin-4-amine or a pharmaceutically acceptable addition salt thereof.
This invention also provides a process for preparing a 1H-imidazo[4,5-c]quinolin-4-amine comprising the steps of:
(i) providing a (1-substituted) (2-substituted) 4-chloro-1H-imidazo[4,5-c]quinoline;
(ii) reacting the compound from step (i) with hydrazine to provide a (1-substituted) (2-substituted) 4-hydrazino-1H-imidazo[4,5-c]quinoline;
(iii) reacting the compound from step (ii) with sodium nitrite to provide a (5-substituted) (6-substituted) 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline;
(iv) reacting the compound from step (iii) with triphenylphosplhine to provide a (1-substituted) (1-substituted) N-triphenylphosphinyl-1H -imidazo[4,5-c]quinolin-4-amine;
(v) hydrolyzing the compound from step (iv) to provide a (1-substituted) (2-substituted) 1H-imidazo[4,5-c]quinolin-4-amine; and
(vi) isolating the (1-substituted) (1-substituted) 1H-imidazo[4,5-c]quinolin-4-amine or a pharmaceutically acceptable addition salt thereof
This invention also provides processes involving certain of the various individual steps set forth above, and combinations of such steps.
In another aspect this invention also provides 4-nitrotetrazolo[1,5-a]quinolin-5-ols, 4-nitrotetrazolo[1,5-a]quinoline-5-sulfonates, (5-substituted)-4-nitrotetrazolo[1,5-a]quinolin-5-amines, (5-substituted)tetrazolo[1,5-a]quinolin-4,5-diamines, (5-substituted) (6-substituted) 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinolines, (1-substituted) (2-substituted) 4-hydrazino- 1H-imidazo[4,5-c]quinolines, and (1-substituted) (2-substituted) N-triphenylphosphinyl-1H-imidazo[4,5-c]quinolin-4-amines.
DETAILED DESCRIPTION OF THE INVENTION
Substituents designated parenthetically herein indicate that the substituent is optionally present, e.g., a 4-(substituted) amino compound contains either an unsubstituted 4-amino group or a substituted 4-amino group.
Reaction Scheme I illustrates processes of the invention and the preparation of compounds of the invention. The unsubstituted compound of Formula I is a known compound and other compounds of Formula I can be prepared by methods known to those skilled in the art and disclosed, e.g., in Chemistry of Heterocyclic Compounds (English Edition), 1981, 16, (12), 1286-1288 (Zyryanov).
Figure US06437131-20020820-C00001
In step (1) of Reaction Scheme I a 4-nitrotetrazolo[1,5-a]quinolin-5-ol of Formula II is provided by nitrating a tetrazolo[1,5-a]quinolin-5-ol of Formula I. Conventional conditions for such reactions are well known. Preferred conditions in the instance where R is hydrogen involve heating in acetic acid in the presence of nitric acid. Preferred conditions in other instances will depend upon the particular tetrazolo[1,5-a]quinolin-5-ol used, and those skilled in the art will be able to select suitable conditions. The product can be isolated from the reaction mixture using conventional methods.
In step (2) of Reaction Scheme I a 4-nitrotetraozolo[1,5-a]quinolin-5-sulfonate of Formula III is provided by reacting a 4-nitrotetrazolo[1,5-a]quinolin-5-ol of Formula II with a sulfonyl halide or preferably a sulfonic anhydride. Suitable sulfonyl halides include alkylsulfonyl halides such as methanesulfonyl chloride and trifluoromethanesulfonyl chloride, and arylsulfonyl halides such as benzenesulfonyl chloride, p-bromobenzenesulfonyl chloride and p-toluenesulfonyl chloride. Suitable sulfonic anhydrides include those corresponding to the above-mentioned sulfonyl halides. Sulfonic anhydrides are preferred in view of the fact that the sulfonate anion generated as a by-product of the reaction is a relatively poor nucleophile and as such does not give rise to undesired side products such as those in which the nitro group is displaced. A particularly preferred sulfonic anhydride is trifluoromethanesulfonic anhydride.
The reaction is preferably carried out by combining a compound of Formula II with a base, preferably an excess of a tertiary amine base (e.g., a trialkylamine base such as triethyl amine) in a suitable solvent such as dichloromethane and then adding the sulfonyl halide or sulfonic anhydride. The addition is preferably carried out in a controlled fashion (e.g., dropwise) and at a reduced temperature (e.g., about 0 °C.). The product can be isolated by conventional methods or it can be carried on without isolation as described below in connection with step (3).
In step (3) of Reaction Scheme I a (5-substituted) 4-nitrotetrazolo[1,5-a]quinolin-5-amine of Formula IV is provided by reacting a 4-nitrotetrazolo[1,5-a]quinolin-5-sulfonate of Formula III with an amine, preferably in the presence of an excess of an amine base in a solvent such as dichloromethane. Suitable amines include ammonia and preferably primary amines. Primary amines provide 5-substituted amino compounds of Formula IV wherein the amino substituent is represented by R1. Particularly preferred amines include isobutylamine and 2-aminomethyl-2-propanol.
The reaction can be carried out by adding an excess of amine to the reaction mixture resulting from Step (2). The reaction can also be carried out by adding an excess of amine to a solution of the compound of Formula III in a solvent such as dichloromethane. As the sulfonate is a relatively facile leaving group the reaction can be run at ambient temperature. The product can be isolated from the reaction mixture using conventional methods.
In step (4) of Reaction Scheme I a (5-substituted)tetrazolo[1,5-a]quinolin-4,5-diamine of Formula V is provided by reducing a (5-substituted) 4-nitrotetrazolo[1,5-a]quinolin-5-amine of Formula IV. Methods for such reduction are well know to those skilled in the art. Preferably the reduction is carried out using a conventional heterogeneous hydrogenation catalyst such as platinum on carbon or palladium on carbon. The reduction can be conveniently carried out on a Paar apparatus in a solvent such as ethanol. The product can be isolated from the reaction mixture using conventional methods.
In step (5) of Reaction Scheme I a (5-substituted) (6-substituted) 6H-10 imidazo[4,5-c]tetrazolo[1,5-a]quinoline of Formula VI is provided by reacting a (5-substituted)tetrazolo[1,5-a]quinolin-4,5-diamine of Formula V with a carboxylic acid or an equivalent thereof. Suitable equivalents to carboxylic acid include acid halides, orthoesters, and 1,1-dialkoxyalkyl alkanoates. The carboxylic acid or equivalent is selected such that it will give rise to the desired 6-substituent in the compound of Formula VI wherein the 6-substituent is designated R2 (e.g., acetyl chloride will give rise to a compound where R2 is methyl). The reaction can be run in the absence of solvent or preferably in an inert solvent in the presence of a carboxylic acid or equivalent thereof with sufficient heating to drive off any alcohol or water formed as a side product of the reaction. The product can be isolated from the reaction mixture using conventional methods.
In step (6) of Reaction Scheme I a (1-substituted) (2-substituted) N-triphenylphosphinyl-1H-imidazo[4,5-c]quinolin-4-amine of Formula VII is provided by reacting a (5-substituted) (6-substituted) 61i-imidazo[4,5-c]tetrazolo[1,5-]quinoline of Formula VI with triphenylphosphine. The reaction can be carried out by combining a compound of Formula VI with triphenylpliosphine in a suitable solvent such as 1,2-dichlorobenzene and heating. The product can be isolated from the reaction mixture using conventional methods.
In step (7) of Reaction Scheme I a (1-substituted) (2-substituted) 1H-imidazo[4,5-c]quinoline-4-amine of Formula VIII is provided by hydrolysis of a (1-substituted) (2-substituted) N-triphenylphosphinyl-1H-imidazo[4,5-c]quinolin-4-amine of Formula VII. Such a reaction can be carried out by general methods well known to those skilled in the art (e.g., by heating in a lower alkanol in the presence of an acid). The product can be isolated from the reaction mixture by conventional means.
In Reaction Scheme I, R′ can be any group that can be incorporated into a sulfonyl halide or a sulfonic anhydride. Alkyl (e.g., methyl), haloalkyl including perfluoroalkyl (e.g., trifluoromethyl) and aryl (e.g., phenyl, halophenyl and tolyl) are all suitable.
Reaction Scheme II illustrates processes of the invention and the preparation of compounds of the invention. Compounds of Formula IX and methods for their preparation are known and disclosed, e.g. in U.S. Pat. Nos. 4,988,815 (Andre), and 5,268,376 (Gerster), both patents being incorporated herein by reference.
Figure US06437131-20020820-C00002
In step (1) of Reaction Scheme II a (5-substituted) 4-nitrotetrazolo[1,5-a]quinolin-5-amine of Formula IV is provided by reacting a (4-substituted) amino-2-chloro-3-nitroquinoline of Formula IX with sodium azide. The reaction can be carried out by combining the compound of Formula IX with sodium azide in a suitable solvent such as N,N-dimethylformamide and heating (about 50° C.). The product can be isolated from the reaction mixture using conventional methods.
Steps (2), (3), (4) and (5) of Reaction Scheme II can be carried out in the same manner as steps (4), (5), (6) and (7) of Reaction Scheme I respectively.
Reaction Scheme III illustrates processes of the invention and the preparation of compounds of the invention. Compounds of Formula X and methods for their preparation are known and disclosed, e.g., in European Patent Application 90.301776.3, U.S. Pat. Nos. 4,689,338 (Gerster), 4,698,348 (Gerster), 4,929,625 (Gerster), 4,988,815 (Andre), 5,268,376 (Gerster), and 5,389,640 (Gerster) all six patents being incorporated herein by reference.
Figure US06437131-20020820-C00003
In step (1) of Reaction Scheme III a (1-substituted) (2-substituted) 4-hydrazino-1H-imidazo[4,5-c]quinoline of Formula XI is provided by reacting a (1 substituted) (2-substituted) 4-chloro-1H-imidazo[4,5-c]quinoline of Formula X with hydrazine. The reaction can be carried out by combining a compound of Formula X with an excess of hydrazine and heating if necessary. The product can be isolated from the reaction mixture using conventional methods.
In step (2) of Reaction Scheme III a (5-substituted) (6-substituted) 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline of Formula VI is provided by reacting a (1-substituted) (2-substituted) 4-hydrazino-1H-imidazo[4,5-c]quinoline of Formula XI with sodium nitrite. The reaction can be carried out by combining the compound of Formula XI with sodium nitrite in a suitable solvent (e.g., water) in the presence of an acid (e.g., acetic acid). The product can be isolated from the reaction mixture using conventional methods.
Steps (3) and (4) of Reaction Scheme III can be carried out in the same manner as steps (6) and (7) of Reaction Scheme I respectively.
The compounds of Formula VIII can be used in the form of acid addition salts such as hydrochlorides, dihydrogen sulfates, trihydrogen phosphates, hydrogen nitrates, methane sulfonates and salts of other pharmaceutically acceptable acids. Pharmaceutically acceptable acid addition salts of Formula VIII are generally prepared by reaction of the respective compound with an equimolar amount of a strong acid, preferably an inorganic acid such as hydrochloric, sulfuric or phosphoric acid or an organic acid such as methanesulfonic acid in a polar solvent. Isolation of the salt is facilitated by the addition of a solvent in which the salt is insoluble (e.g., diethyl ether).
Processes of the invention provide as a final product a 1H-imidazo[4,5-c]quinolin-4-amine, preferred embodiments of which can be represented by Formula VIII.
Preferably the 1H -imidazo[4,5-c]quinolin-4-amine is a compound defined by one of Formulas XXI-XXV below:
Figure US06437131-20020820-C00004
wherein
R11 is selected from the group consisting of alkyl, hydroxyalkyl, acyloxyalkyl, benzyl, (phenyl)ethyl and phenyl, said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms and halogen, with the proviso that if said benzene ring is substituted by two of said moieties, then said moieties together contain no more than 6 carbon atoms; acylaminoalkyl wherein the alkyl moiety contains two to four carbon atoms; disubstitute aminoalkyl wherein tile alkyl moiety contains two to four carbon atoms; morpholinoalkyl wherein the alkyl moiety contains two to four carbon atoms; R21 is selected from the group consisting of hydrogen, alkyl of one to about eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms and halogen, with the proviso that when the benzene ring is substituted by two of said moieties, then the moieties together contain no more than 6 carbon atoms; and each RA is independently selected from the group consisting of alkoxy of one to about four carbon atoms, halogen and alkyl of one to about four carbon atoms, and n is an integer from 0 to 2, with the proviso that if n is 2, then said RA groups together contain no more than 6 carbon atoms;
Figure US06437131-20020820-C00005
wherein
R12 is selected from the group consisting of straight chain or branched chain alkenyl containing 2 to about 10 carbon atoms and substituted straight chain or branched chain alkenyl containing 2 to about 10 carbon atoms, wherein the substituent is selected from the group consisting of straight chain or branched chain alkyl containing 1 to about 4 carbon atoms and cycloalkyl containing 3 to about 6 carbon atoms; and cycloalkyl containing 3 to about 6 carbon atoms substituted by straight chain or branched chain alkyl containing 1 to about 4 carbon atoms; and
R22 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl containing one to about eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of straight chain or branched chain alkyl containing one to about four carbon atoms, straight chain or branched chain alkoxy containing one to about four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than 6 carbon atoms; and
each RB is independently selected from the group consisting of straight chain or branched chain alkoxy containing one to about four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to about four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said RB groups together contain no more than 6 carbon atoms;
Figure US06437131-20020820-C00006
wherein
R23 is selected from the group consisting of hydrogen, straight chain or branched chain alkyl of one to about eight carbon atoms, benzyl, (phenyl)ethyl and phenyl, the benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of straight chain or branched chain alkyl of one to about four carbon atoms, straight chain or branched chain alkoxy of one to about four carbon atoms, and halogen, with the proviso that when the benzene ring is substituted by two such moieties, then the moieties together contain no more than 6 carbon atoms; and
each RC is independently selected from the group consisting of straight chain or branched chain alkoxy of one to about four carbon atoms, halogen, and straight chain or branched chain alkyl of one to about four carbon atoms, and n is an integer from zero to 2, with the proviso that if n is 2, then said RC groups together contain no more than 6 carbon atoms;
Figure US06437131-20020820-C00007
wherein R14 is —CHxRy
wherein
Ry is hydrogen or a carbon-carbon bond, with the proviso that when Ry is hydrogen Rx is alkoxy of one to about four carbon atoms, hydroxyalkoxy of one to about four carbon atoms, 1-alkynyl of two to about ten carbon atoms, tetrahydropyranyl, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, 2-, 3-, or 4-pyridyl, and with the further proviso that when Ry is a carbon-carbon bond Ry and Rx together form a tetrahydrofuranyl group optionally substituted with one or more substituents independently selected from the group consisting of hydroxy and hydroxyalkyl of one to about four carbon atoms;
R24 is selected from the group consisting of hydrogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen; and
RD is selected from the group consisting of hydrogen, straight chain or branched chain alkoxy containing one to about four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to about four carbon atoms;
Figure US06437131-20020820-C00008
wherein
R15 is selected from the group consisting of: hydrogen; straight chain or branched chain alkyl containing one to about ten carbon atoms and substituted straight chain or branched chain alkyl containing one to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; straight chain or branched chain alkenyl containing two to about ten carbon atoms and substituted straight chain or branched chain alkenyl containing two to about ten carbon atoms, wherein the substituent is selected from the group consisting of cycloalkyl containing three to about six carbon atoms and cycloalkyl containing three to about six carbon atoms substituted by straight chain or branched chain alkyl containing one to about four carbon atoms; hydroxyalkyl of one to about six carbon atoms; alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about six carbon atoms; acyloxyalkyl wherein the acyloxy moiety is alkanoyloxy of two to about four carbon atoms or benzoyloxy, and the alkyl moiety contains one to about six carbon atoms; benzyl; (phenyl)ethyl; and phenyl; said benzyl, (phenyl)ethyl or phenyl substituent being optionally substituted on the benzene ring by one or two moieties independently selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen, with the proviso that when said benzene ring is substituted by two of said moieties, then the moieties together contain no more than six carbon atoms; acylaminoalkyl wherein the alkyl moiety contains two to four carbon atoms; disubstituted aminoalkyl wherein the alkyl moiety contains two to four carbon atoms; morpholinoalkyl wherein the alkyl moiety contains two to four carbon atoms;
R25 is
Figure US06437131-20020820-C00009
wherein
RS and RT are independently selected from the group consisting of rogen, alkyl of one to about four carbon atoms, phenyl, and substituted phenyl wherein the substituent is selected from the group consisting of alkyl of one to about four carbon atoms, alkoxy of one to about four carbon atoms, and halogen;
X is selected from the group consisting of alkoxy containing one to about four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, haloalkyl of one to about four carbon atoms, alkylamido wherein the alkyl group contains one to about four carbon atoms, amino, substituted amino wherein the substituent is alkyl or hydroxyalkyl of one to about four carbon atoms, azido, alkylthio of one to about four carbon atoms; and
RE is selected from the group consisting of hydrogen, straight chain or branched chain alkoxy containing one to about four carbon atoms, halogen, and straight chain or branched chain alkyl containing one to about four carbon atoms;
or a pharmaceutically acceptable salt of any of the foregoing.
The compounds recited above are disclosed and claimed in the several patents noted above in the Summnary of the Invention and discussed below.
In instances where n can be zero, one, or two, n is preferably zero or one.
The substituents RA-RE above are species embraced by It. The preferred R substituent is hydrogen.
The substituents R11-R15 above are species embraced by R1. The preferred R1 substituents are alkyl of one to about six carbon atoms, hydroxy alkyl wherein the alkyl moiety contains one to about 6 carbon atoms, and arylalkyl wherein the alkyl moiety contains one to about three carbon atoms. Most preferably the R1 substituent is 2-methylpropyl, 2-hydroxy-2-methylpropyl, benzyl or phenylethyl.
The substituents R21-R25 above are species embraced by R2 The preferred R2 substituents are hydrogen, alkyl of one to about four carbon atoms, alkoxyalkyl wherein the alkoxy moiety contains one to about four carbon atoms and the alkyl moiety contains one to about four carbon atoms, hydroxyl alkyl wherein the alkyl moiety contains one to about four carbon atoms, haloalkyl wherein the alkyl moiety contains one to about four carbon atoms, and aryloxymethyl. Most preferably the R2 substituent is hydrogen, methyl, ethoxymethyl, or benzyl.
Certain R substituents, R1 substituents, and R2 substituents will be incompatible with the particular reaction conditions described above in connection with the Reaction Schemes. Those skilled in the art, however, will be able to select alternative conditions under which the several steps can be carried out and/or methods of functional group protection and manipulation that will allow the use of the processes of the invention in the preparation of 1H-imidazo[4,5-c]quinolin-4-amines of diverse structures.
Certain 1H-imidazo[4,5-c]quinolin-4-amines have been disclosed as antiviral agents (see, e.g., European Patent Application 90.301776.3 (Gerster), U.S. Pat. Nos. 4,689,338 (Gerster), 4,929,624 (Gerster), 5,266,575 (Gerster), 5,268,376 (Gerster), and 5,389,640 (Gerster) all five patents incorporated herein by reference). Certain of these compounds are also known to induce biosynthesis of cytokines such as interferons, interleukins, and tumor necrosis factor in humans and in mice.
The Examples below are intended to illustrate the invention. All parts and percentages are by weight unless otherwise indicated.
Example 1 Tetrazolo[1,5-a]quinolin-5-ol
Part A
Anthranilic acid (274.3 g) and acetic anhydride (1.1 L) were combined then heated at reflux for 3.5 hours. The reaction mixture was concentrated under vacuum. The residue was combined with methanol (550 mL) then concentrated under vacuum to provide 2-methiyl-4-oxo-3,1-benzoxazine as a brown oil.
Part B
The crude 2-methyl-4-oxo-3,1-benzoxazine was dissolved in acetic acid (1.9 L). Sodium azide (130.0 g) was added to the solution in portions with stirring. The reaction mixture was cooled in an ice bath to maintain the reaction temperature at 25 to 30° C. during the addition. The reaction mixture was allowed to stir at ambient temperature over the weekend. The acetic acid was removed under vacuum to provide a white solid. The solid was combined with 10% sodium hydroxide (1.4 L) then heated on a steam bath for 1 hour. Additional sodium hydroxide (120 g of 50% sodium hydroxide) was added. The mixture was heated on a steam bath for an additional hour then allowed to cool to ambient temperature overnight. Additional sodium hydroxide (120 g of 50% sodium hydroxide) was added. The mixture was heated on a steam bath for 2 hours then allowed to cool. The reaction mixture was poured with rapid stirring into a mixture of concentrated hydrochloric acid (1.0 L) and ice (3 L). The resulting mixture was stirred at ambient temperature overnight. A precipitate was isolated by filtration, rinsed with water then slurried with water (4 L). The solid was isolated by filtration, rinsed with water then oven dried at 50° C. to provide 278.0 g of crude 2-(5-methyl-1H-tetrazol-1-yl)benzoic acid as a tan solid, m.p. 157-160 °C. The crude material was dissolved in 10% sodium hydroxide (2.5 L). The resulting solution was heated (95-99° C.) for 2.5 hours, cooled, then poured with vigorous stirring into a mixture of concentrated hydrochloric acid (500 mL) and ice (5 L). The resulting mixture was allowed to stir for 2 hours. The precipitate was isolated by filtration, rinsed with water, then slurried with water (3 L). The solid was isolated by filtration, rinsed with water then dried overnight at ambient temperature to provide 228 g of 2-(5-metlhyl-1H-tetrazol-1-yl)benzoic acid, m.p. 164-166° C.
Part C
Acetone (3.2 L) and 2-(5-methyl-1H-tetrazol-1-yl)benzoic acid (228 g) were combined then stirred at ambient temperature for 15 minutes. Potassium carbonate (228 g) was added to the reaction mixture in a single portion. Iodoethane (366.8 g) was added dropwise to the reaction mixture producing a slight exotherm. The reaction mixture was heated at reflux for about 4 hours then stirred overnight while cooling to ambient temperature. The precipitated salts were removed by filtration then rinsed with acetone. The combined filtrates were evaporated under vacuum. The residue was dissolved in dichlorometliane (1.5 L). The dichloromethane solution was washed with water (1.5 L), dried over magnesium sulfate then concentrated under vacuum to provide 227 g of ethyl-2-(5-methyl-1H-tetrazol-1-yl)benzoate as a white solid m.p. 98-100° C.
Part D
Potassium ethoxide (173.5 g) was added in portions with stirring to a mixture of ethyl-2-(5-methyl-1H-tetrazol-1-yl)benzoate (227 g) and N,N-dimethylformamide (1.6 L). The reaction mixture was cooled with an ice bath to control the resulting exotherm. The reaction mixture was stirred overnight at ambient temperature then quenched with water (17 L). The ply was adjusted to pH 5 with acetic acid (170 mL). The resulting precipitate was isolated by filtration, rinsed with water then reslurried with water (2.5 L). The solid was isolated by filtration, rinsed with water then oven dried (55 to 60° C.) for 16 hours to provide 169.0 g of a white solid. A 3.0 g sample was recrystallized from ethanol/dichloromethane to provide tetrazolo[15-a]quinolin-5-ol as a white solid, m.p. 248° C. (dec.). Analysis: Calculated for C9H6N4O: %C, 58.06; %H, 3.25; %N, 30.09; Found: %C, 58.02; %H, 3.29; %N, 30.20
EXAMPLE 2 4-Nitrotetrazolo[1,5-a]quinolin-5-ol Hydrate
Tetrazolo[1,5-a]quinolin-5-ol (10 g, 54 mmole, Example 1) was suspended in acetic acid (200 mL) then warmed to 40° C. Nitric acid (4 mL of 16M, 59 mmole) was added to the reaction mixture. The reaction mixture was heated at 80° C. for 30 minutes then allowed to cool to ambient temperature. The resulting precipitate was isolated by filtration, rinsed with water then recrystallized from isopropanol/water to provide 8.1 g of 4-nitrotetrazolo[1,5-a]quinolin-5-ol hydrate as light yellow plates, m.p. 186.5-187° C. Analysis: Calculated for C9H5N5O3. H2O: %C, 43.38; %H, 2.83; %N, 28.10; Found: %C, 43.27; %H, 2.84; %N, 28.25.
EXAMPLE 3 2-Methyl-[(4-nitro-5-tetrazolo[1,5-a]quinolinyl)amino]-2-propanol
Sodium azide (19.5 g, 0.3 moles), 2-methyl-[(2-chloro-3-nitroquinolin-4-yl)amino]-2-propanol (29.6 g, 0.10 mole, U.S. Pat. No. 4,988,815 Example 12) and N,N-dimethylformamide (100 mL) were added to a jacketed 1 liter round bottom flask with the outside portion containing acetone. The reaction mixture was stirred with a stirring bar and the acetone refluxed to provide a constant internal reaction temperature of 53° C. After 18 hours the reaction mixture was diluted with water (100 mL). The resulting yellow precipitate was isolated by filtration then washed with 50% N,N-dimethylformamide/water until the washes became light colored. The yellow/green solid was then washed with water, pressed dry and washed with ether. The solid was air dried to provide 27.2 g of crude product as a yellow/light green solid. This material was recrystallized from ethanol/dichloromethane to provide 2-methyl-[(4-nitro-5-tetrazolo[1,5-a]quinolinyl)amino]-2-propanol as a yellow crystalline solid, m.p. 204° C. (dec.). Analysis: Calculated for: C13H14N6O3: %C, 51.65; %H, 4.67; %N, 27.8; Found: %C, 51.30; %H, 4.69; %N, 27.43.
EXAMPLE 4
[(4-Amino-5-tetrazolo[1,5-c]quinolinyl)amino]-2-methyl-2-propanol 2-Methyl-[(4-nitro-5-tetrazolo[1,5-a]quinolinyl)amino]-2-propanol (30.2 g, 0.10 mole, Example 3), ethanol (300 mL) and 5% Pd/C (1.0 g of 50% water wet) were placed in a Paar apparatus. The mixture was hydrogenated. The mixture was diluted with diclilorometliane then filtered to remove the catalyst. The filtrate was concentrated under vacuum. The crude product was recrystallized from ethanol to provide 20.5 g of [(4-amino-5-tetrazolo[1,5-c]quinolinyl)amino]-2-methyl-2-propanol as a yellow/green crystalline solid, m.p. 164-167° C. Analysis: Calculated for C13H16N6O: %C, 57.33; %H, 5.92; %N, 30.88; Found: %C, 56.94; %H, 5.88; %N, 30.80.
EXAMPLE 5 α,α-Dimethyl-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline-6-ethanol
[(4-Amino-5-tetrazolo[1,5-c]quinolinyl)amino]-2-methyl-2-propanol (5 g, 0.18 mole, Example 4) was dissolved in triethyl orthoforiniate (17 g). The solution was heated at 120° C. for 20 hours. The reaction mixture was allowed to cool to ambient temperature then it was diluted with 1 N hydrochloric acid. Formic acid (20 mL) was added to the mixture which was then heated at reflux for an hour. The reaction mixture was concentrated under vacuum then neutralized with sodium hydroxide. The crude product was recrystallized from ethanol/ethyl acetate to provide α,α-dimethyl-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline-6-ethanol as a solid, m.p. 245-248° C. Analysis: Calculated for C14H14N6O: %C, 59.55; %H, 4.99; %N, 29.77; Found: %C, 59.44; %H, 4.93; %N, 29.65.
EXAMPLE 6 α,α,5-Trimethyl-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline-6-ethanol
Acetyl chloride (16 g, 0.020 mole) was added dropwise to a solution of[(4-amino-5-tetrazolo[1,5-c]quinolinyl)amino]-2-methyl-2-propanol (5 g, 0.18 mole, Example 4) in acetonitrile. The reaction mixture was stirred at ambient temperature for 4 hours. The resulting precipitate was isolated by filtration then dissolved in acetic acid (about 50 mL). This solution was refluxed for 2 hours then neutralized with carbonate. The crude product was isolated by filtration then recrystallized initially from hexanelethyl acetate then from ethanol/ethyl acetate to provide α,α,5-trimethyl-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline-6-ethanol as a solid, m.p. 202-205° C. Analysis: Calculated for C15H16N6O: %C, 60.8; %H, 5.44; %N, 28.36; Found: %C, 60.68; %H, 5.48; %N, 28.28.
EXAMPLE 7
4-Hydrazino-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline 4-Chloro-1-(2-methylpropyl)-1H-imidazo[4,5-c]qinoline (10.0 g, 0.0385 moles, U.S. Pat. No. 4,689,338 Example 77) was added to hydrazine (30 mL). The mixture heated rapidly to reflux. The solid dissolved with a vigorous heat of reaction then a precipitate formed as the reaction mixture refluxed. The reaction mixture was diluted with water. The precipitate was isolated by filtration then suspended in water (100 mL). The solid was brought into solution by the addition of acetic acid. The solution was filtered to remove traces of undissolved solid. The filtrate was made basic by the addition of ammonium hydroxide. The resulting precipitate was isolated by filtration, washed with water then dried to provide 8.0 g of crude product as a white solid. A sample of this material was recrystallized from methanol to provide 4-hydrazino-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline, m.p. 202-205° C. Analysis: Calculated for C14H17N5: %C, 65.86; %H, 6.71; %N, 27.43; Found: %C, 65.20; %H, 6.6; %N, 27.5.
EXAMPLE 8 6-(2-Methylpropyl)-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline
A solution of sodium nitrite (2.0 g, 3 mmole) in water (5 mL) was added to a solution of 4-hydrazino-1-(2-methylpropyl)-1H-imidazo[4,5-c]quinoline (4.0 g, 15.7 mmole, Example 7) in a mixture of acetic acid (5 mL) and water (50 mL). The reaction mixture was stirred at ambient temperature for 15 minutes. A precipitate was isolated by filtration, washed with water then air dried to provide 4.1 g of crude product. This material was recrystallized from dichloromethanelethanol to provide 3.0 g of 6-(2-methylpropyl)-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline as a cream colored crystalline solid, m.p. 208-212° C. Analysis: Calculated for C14H14N6: %C, 63.14; %H, 5.30; %N, 31.56; Found: %C, 62.60; %H, 5.2; %N, 31.5.
EXAMPLE 9 α,α-Dimethyl-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline-6-ethanol
A suspension of 4-chloro-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol (1.0 g, 3.6 mmole, U.S. Pat. No. 4,689,338 Example 189 Part D) in hydrazine (3 mL, 6.9 mmole) was heated on a steam bath for 1 hour then diluted with water. The resulting precipitate was isolated by filtration. The solid was dissolved in a mixture of acetic acid (2 mL) and water (15 mL) then combined with a solution of sodium nitrite (0.5 g) in water. The resulting precipitate was isolated by filtration, washed with water and dried to provide 0.71 g of α,α-dimethyl-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline-6-ethianol as a white solid, m.p. 246-247° C. (shrunk at 230° C.). Analysis: Calculated for C14H14N6O: %C, 59.56; %H, 5.00; %N, 29.77; Found: %C, 59.45; %H, 5.06; %N, 29.51.
EXAMPLE 10 1-(2-Methylpropyl)-N-triphenylphosphinyl-1H-imidazo[4,5-c]quinolin-4-amine
6-(2-Methylpropyl)-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline (0.2 g, 0.75 mmole, Example 8), triphenylpllosphine (0.4 g, 1.5 mmole) and 1,2-dichlorobenzene (5 mL) were combined and heated at reflux overnight. The reaction mixture was concentrated under vacuum then diluted with cyclohexane (25 mL). The resulting precipitate was isolated by filtration, washed with cyclohexane then dried to provide 1-(2-metliylpropyl)-N-triphenylpihospihinyl-1H-imidazo[4,5-]quinolin-4-amine as a solid, m.p. 209-210 °C. Analysis: Calculated for C32H29N4P: C, 76.78; %H, 5.84; %N, 11.19; Found: %C, 76.03; %H, 5.87; %N, 11.09.
EXAMPLE 11 4-Amino-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol
Triphenylphosphine (4.5 g, 17.0 mmole) was added to a mixture of α,α-dimethyl-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline-6-ethanol (2.4 g, 8:5 mmole, Example 9) and 1,2-dichlorobenzene. The reaction mixture was heated at reflux for 3 hrs then concentrated under vacuum. The residue was combined with methanol (400 mL) and hydrochloric acid (50 mL of 0.5N) then heated on a steam bath for 2 hours. The resulting precipitate was isolated by filtration then washed with ether. The solid was dissolved in water and the solution was made basic with 10% sodium hydroxide. After stirring for 30 minutes, the reaction mixture was filtered. The collected solid was rinsed with water and ether then recrystallized from N,N-dimethylforniamide/ethanol to provide about 1 g of 4-amino-α,α-dimethyl-1H-imidazo[4,5-c]quinoline-1-ethanol as a solid, m.p. 271-273° C. Analysis: Calculated for C14H16N4O: %C, 65.6; %H, 6.29; %N, 21.86; Found: %C, 65.37; %H, 6.26; %N, 21.61.
EXAMPLE 12 1-(2-Methylpropyl)-1H-iinidazo[4,5-c]quinolin-4-amine
1-(2-Methylpropyl)-N-triphenylphosphinyl-1H-imidazo[4,5-c]quinolin-4-amine (100 mg, Example 10) was suspended in a mixture of methanol (3 mL) and hydrochloric acid (10 mL of 0.5N). The mixture was heated on a steam bath for 2 hours then allowed to stand at ambient temperature overnight. The reaction mixture was filtered. The filtrate was made basic with 10% sodium hydroxide. The resulting precipitate was isolated by filtration then dried to provide 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine. The spectral properties of this material matched those of an authentic sample.
EXAMPLE 13 4-Nitrotetrazolo[1,5-a]quinolin-5-ol
Aqueous sodium hydroxide (30 g of 50%) was added to a suspension of 2-methyl-[(4-nitro-5-tetrazolo[1,5-a]quinolinyl)amino]-2-propanol (34.0 g, 0.1125 mole, Example 3) in water (500 mL). The mixture was heated on a steam bath and the solid dissolved rapidly. The solution was heated for about 30 minutes and then upon stirring a solid began to precipitate. The mixture was made acidic with 6N hydrochloric acid. The resulting solid was isolated by filtration; washed in succession with water, ethanol and ether; then dried under vacuum at 100 °C. to provide 23.2 g of crude product as a pale yellow/green solid. A sample (3.2 g) was recrystallized initially from methanol/dichloromethane and then from toluene to provide 4-nitrotetrazolo[1,5-a]quinolin-5-ol. Analysis: Calculated for C9H5N5O3: %C, 46.76; %H, 2.18; %N, 30.29; Found: %C, 46.85; %H, 2.23; %N, 29.91.
EXAMPLE 14 4-Nitrotetrazolo[1,5-a]quinolin-5-yl]trifluoromethanesulfonate
Triethylamine (0.6 mL, 4.32 mmole) was added to a suspension of 4-nitrotetrazolo[1,5-a]quinolin-5-ol (1.0 g, 4.32 mmoles, Example 2) in dicliloromethane (20 mL). The reaction mixture was cooled to 0° C. Trifle anhydride (0.73 mL, 4.32 mmole) was added. The reaction mixture was stirred for 3 hours at 0° C. The reaction mixture was diluted with dichloromethane (50 mL), washed with 0.5 N hydrochloric acid, dried over magnesium sulfate and concentrated under vacuum. The residue was combined with liexanes (100 mL), refluxed for 15 minutes and filtered. A solid precipitated from the filtrate on cooling. The solid was isolated by filtration and dried to provide 0.2 g of 4-nitrotetrazolo[1,5-a]quinolin-5-yl]trifluoromethanesulfonate as a white solid, m.p. 132-134° C. Analysis: Calculated for C10H14F3N5O5S: %C, 33.07; %H, 1.11; %N, 19.28; Found: %C, 33.19; %H, 1.28; %N, 19.61.
EXAMPLE 15 N-(2-Methylpropyl)-4-nitrotetrazolo[1,5-a]quinolin-5-amine
Isobutylamine (1 mL) was added to a solution of 4-nitrotetrazolo[1,5-a]quinolin-5-yl]trifluoromethanesulfonate (0.5 g, 1.37 mmole, Example 14) in dichloromethane (50 mL,). The reaction mixture was stirred at ambient temperature for 4 hours, diluted with dichloromethane (50 mL), washed with water (2×50 mL), dried over magnesium sulfate then concentrated under vacuum. The residue was purified by filtering through a layer of silica gel eluting with 2% methanol in dichloromethane. The resulting yellow solid was recrystallized from ethyl acetate to provide 0.31 g of N-(2-methylpropyl)-4-nitrotetrazolo[1,5-a]quinolin-5-amine, m.p. 152-154° C. alysis: Calculated for C13H14N6O2: %C, 54.54; %H, 4.93; %N, 29.35; Found: %C, 54.45; %H, 4.73; %N, 29.47.
EXAMPLE 16 N5-(2-Methylpropyl)tetrazolo[1,5-a]quinoline-4,5-diamine
N-(2-Methylpropyl)-4-nitrotetrazolo[1,5,-a]quinolin-5-amine (1.0 g, 3.5 mmole, Example 15), ethanol (100 mL) and Pt/C were placed in a Paar apparatus. The mixture was hydrogenated at 50 psi (3.44×105 Pa). The reaction mixture was filtered to remove the catalyst then concentrated under vacuum. The residue was recrystallized from ethyl acetate to provide 0.35 g of N5-(2-methylpropyl)tetrazolo[1,5-a]quinoline-4,5-diamine as off white needles, m.p. 148-150° C. Analysis: Calculated for C13H16N6: %C, 60.92; %H, 6.29; %N, 32.79; Found: %C, 60.94; %H, 6.25; %N, 32.93.
EXAMPLE 17 6-(2-Methylpropyl)-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline
N5-(2-Methylpropyl)tetrazolo[1,5-a]quinoline-4,5-diamine (0.2 g, 0.78 mmole, Example 16) was combined with dietlioxyrnethlyl acetate (2 mL) and heated on a steam bath for 3 hours. Water (10 mL) and 10% sodium hydroxide (2 mL) were added and the reaction mixture was heated on a steam bath for 1 hour. A solid was isolated by filtration then recrystallized from methanol/ethyl acetate to provide 0.16 g of 6-(2-methylpropyl)-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline as a white crystalline solid, m.p. 210-212° C. Analysis: Calculated for C14H14N6: %C, 63.14; %H, 5.30; %N, 31.56; Found: %C, 63.12; %H, 5.32; %N, 31.61.
EXAMPLE 18 N-(1,1-Dimethylethyl)-4-nitrotetrazolo[1,5-a]quinolin-5-amine
Triethylamine (6 mL), 4-nitrotetrazolo[1,5-a]quinolin-5-ol (8.7 g, 37.6 mmole, Example 13) and dichloromethane (100 mL) were combined and stirred at ambient temperature until a solution was obtained. The solution was cooled to −115° C. Trifle anhydride (6.5 mL) was added in portions to the cooled solution. The reaction mixture was allowed to warm to ambient temperature then filtered through a layer of silica gel. The filtrate was washed with cold dilute hydrochloric acid then dried over magnesium sulfate. Triethylamine (5.25 mL) was added to the dichloromethane solution and the resulting mixture was stirred for about 10 minutes. tert-Butylamine (4.2 mL) was added dropwise to the reaction mixture. The reaction mixture was heated on a steam bath for about 15 minutes. The resulting solid was isolated by filtration then purified by silica gel chromatography to provide the crude product as a yellow solid. This material was recrystallized from ethanollwater to provide 5 g of N-(1,1-dimethyletliyl)-4-nitrotetrazolo[1,5-a]quinolin-5-amine. The structure was confirmed by nuclear magnetic resonance spectroscopy.
EXAMPLE 19 N5-(1,1-Dimethylethyl)tetrazolo[1,5-a]quinoline-4,5-diamine
N-(1,1-dimethylethyl)-4-nitrotetrazolo[1,5-a]quinolin-5-amine (4.2 g, Example 18), ethanol (100 mL) and Pt/C (0.5 g) were placed in a Paar apparatus. The mixture was hydrogenated. The reaction mixture was filtered to remove catalyst then concentrated to dryness under vacuum. The residue was recrystallized from ethyl acetate/dichloromethane to provide N5-(1,1-dimethylethyl)tetrazolo[1,5-a]quinoline-4,5-diamine as a pale blue crystalline solid.
EXAMPLE 20 6-(1,1-Dimetiiylethyl)-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline
Diethoxymethyl acetate (1.9 mL) was added dropwise to a solution of N5-(1,1-dimethylethyl)tetrazolo[1,5-a]quinoline-4,5-diamine (1.5 g, 5.9 mmole, Example 19) in acetic acid (15 mL). The reaction mixture was heated on a steam bath for 1 hour then made basic with sodium hydroxide. The resulting precipitate was isolated by filtration then recrystallized from ethanol to provide 6-(1,1-dimethylethyl)-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline, m.p. 224-226° C. Analysis: Calculated for C14H14N6: %C, 63.13; %H, 5.29; %N, 31.56; Found: %C, 62.90; %H, 5.44; %N, 11.52.
EXAMPLE 21 6H-Imidazo[4,5-c]tetrazolo[1,5-a]quinoline
6-(1,1 -Dimethylethyl)-6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline (1 g, 3.8 mmole, Example 20) was added to hydrochloric acid (5 mL of 6N); water (20 mL) was added and the mixture was heated on a steam bath for 1 hour. The reaction mixture was allowed to cool to ambient temperature then made basic (pH 11) by the addition of sodium hydroxide solution. The resulting precipitate was isolated by filtration, dried then recrystallized from N,N-dimetllylformamide to provide 0.65 g of the desired product as a solid. A sample of this material was refluxed in a large amount of dichloromethanetmethanol, isolated by filtration, then dried to provide 6H-imidazo[4,5-c]tetrazolo[1,5-a]quinoline as a solid, m.p. >300° C. Analysis: Calculated for C10H6N6: %C, 57.14; %H, 2.88; %N, 39.98; Found: %C, 56.89; %H, 3.10; %N 39.34. The structure was confirmed by both mass spectroscopy and nuclear magnetic resonance spectroscopy.

Claims (2)

What is claimed is:
1. A compound of Formula III
Figure US06437131-20020820-C00010
wherein R1 is selected from the group consisting of alkyl, haloalkyl and aryl.
2. A compound according to claim 1 wherein R1 is trifluoromethyl.
US09/678,192 1996-06-21 2000-10-04 Process for preparing imidazoquinolinamines Expired - Lifetime US6437131B1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US09/678,192 US6437131B1 (en) 1996-06-21 2000-10-04 Process for preparing imidazoquinolinamines
US10/180,678 US6534654B2 (en) 1996-06-21 2002-06-26 Process for preparing imidazoquinolinamines
US10/352,606 US6613902B2 (en) 1996-06-21 2003-01-28 Process for preparing imidazoquinolinamines
US10/360,210 US6624305B2 (en) 1996-06-21 2003-02-06 Process for preparing imidazoquinolinamines
US10/624,014 US6897314B2 (en) 1996-06-21 2003-07-21 Process for preparing imidazoquinolinamines
US10/974,258 US7026482B2 (en) 1996-06-21 2004-10-27 Process for preparing imidazoquinolinamines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US08/673,712 US5741908A (en) 1996-06-21 1996-06-21 Process for reparing imidazoquinolinamines
US09/061,401 US5998619A (en) 1996-06-21 1998-04-16 Process for preparing imidazoquinolinamines
US09/375,587 US6150523A (en) 1996-06-21 1999-08-17 Process for preparing imidazoquinolinamines
US09/678,192 US6437131B1 (en) 1996-06-21 2000-10-04 Process for preparing imidazoquinolinamines

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/375,587 Division US6150523A (en) 1996-06-21 1999-08-17 Process for preparing imidazoquinolinamines

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/180,678 Division US6534654B2 (en) 1996-06-21 2002-06-26 Process for preparing imidazoquinolinamines

Publications (1)

Publication Number Publication Date
US6437131B1 true US6437131B1 (en) 2002-08-20

Family

ID=24703817

Family Applications (9)

Application Number Title Priority Date Filing Date
US08/673,712 Expired - Lifetime US5741908A (en) 1996-06-21 1996-06-21 Process for reparing imidazoquinolinamines
US09/061,401 Expired - Lifetime US5998619A (en) 1996-06-21 1998-04-16 Process for preparing imidazoquinolinamines
US09/375,587 Expired - Lifetime US6150523A (en) 1996-06-21 1999-08-17 Process for preparing imidazoquinolinamines
US09/678,192 Expired - Lifetime US6437131B1 (en) 1996-06-21 2000-10-04 Process for preparing imidazoquinolinamines
US10/180,678 Expired - Lifetime US6534654B2 (en) 1996-06-21 2002-06-26 Process for preparing imidazoquinolinamines
US10/352,606 Expired - Lifetime US6613902B2 (en) 1996-06-21 2003-01-28 Process for preparing imidazoquinolinamines
US10/360,210 Expired - Lifetime US6624305B2 (en) 1996-06-21 2003-02-06 Process for preparing imidazoquinolinamines
US10/624,014 Expired - Fee Related US6897314B2 (en) 1996-06-21 2003-07-21 Process for preparing imidazoquinolinamines
US10/974,258 Expired - Fee Related US7026482B2 (en) 1996-06-21 2004-10-27 Process for preparing imidazoquinolinamines

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US08/673,712 Expired - Lifetime US5741908A (en) 1996-06-21 1996-06-21 Process for reparing imidazoquinolinamines
US09/061,401 Expired - Lifetime US5998619A (en) 1996-06-21 1998-04-16 Process for preparing imidazoquinolinamines
US09/375,587 Expired - Lifetime US6150523A (en) 1996-06-21 1999-08-17 Process for preparing imidazoquinolinamines

Family Applications After (5)

Application Number Title Priority Date Filing Date
US10/180,678 Expired - Lifetime US6534654B2 (en) 1996-06-21 2002-06-26 Process for preparing imidazoquinolinamines
US10/352,606 Expired - Lifetime US6613902B2 (en) 1996-06-21 2003-01-28 Process for preparing imidazoquinolinamines
US10/360,210 Expired - Lifetime US6624305B2 (en) 1996-06-21 2003-02-06 Process for preparing imidazoquinolinamines
US10/624,014 Expired - Fee Related US6897314B2 (en) 1996-06-21 2003-07-21 Process for preparing imidazoquinolinamines
US10/974,258 Expired - Fee Related US7026482B2 (en) 1996-06-21 2004-10-27 Process for preparing imidazoquinolinamines

Country Status (15)

Country Link
US (9) US5741908A (en)
EP (1) EP0912565B1 (en)
JP (1) JP4139915B2 (en)
KR (3) KR20040029477A (en)
AT (1) ATE264326T1 (en)
AU (1) AU721036B2 (en)
CA (1) CA2257846C (en)
DE (1) DE69632207T2 (en)
DK (1) DK0912565T3 (en)
ES (1) ES2215203T3 (en)
IL (5) IL148318A0 (en)
NO (4) NO316564B1 (en)
NZ (1) NZ333169A (en)
PT (1) PT912565E (en)
WO (1) WO1997048704A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070100146A1 (en) * 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
US20090202626A1 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
US20090324551A1 (en) * 2005-08-22 2009-12-31 The Regents Of The University Of California Office Of Technology Transfer Tlr agonists
US20100210598A1 (en) * 2009-02-11 2010-08-19 Regents Of The University Of California, San Diego Toll-like receptor modulators and treatment of diseases
US8357374B2 (en) 2007-02-07 2013-01-22 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
US9066940B2 (en) 2009-02-06 2015-06-30 Telormedix, Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6608201B2 (en) * 1992-08-28 2003-08-19 3M Innovative Properties Company Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
UA67760C2 (en) * 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
US6518280B2 (en) 1998-12-11 2003-02-11 3M Innovative Properties Company Imidazonaphthyridines
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
KR20010101420A (en) 1999-01-08 2001-11-14 캐롤린 에이. 베이츠 Formulations and Methods for Treatment of Mucosal Associated Conditions With an Immune Response Modifier
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6573273B1 (en) 1999-06-10 2003-06-03 3M Innovative Properties Company Urea substituted imidazoquinolines
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6756382B2 (en) 1999-06-10 2004-06-29 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6916925B1 (en) 1999-11-05 2005-07-12 3M Innovative Properties Co. Dye labeled imidazoquinoline compounds
JP3436512B2 (en) * 1999-12-28 2003-08-11 株式会社デンソー Accelerator device
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US6545016B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Amide substituted imidazopyridines
US6667312B2 (en) * 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) * 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
UA74852C2 (en) * 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6664264B2 (en) * 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
CA2598144A1 (en) * 2000-12-08 2006-08-31 3M Innovative Properties Company Compositions and methods for targeted delivery of immune response modifiers
US6545017B1 (en) 2000-12-08 2003-04-08 3M Innovative Properties Company Urea substituted imidazopyridines
US7226928B2 (en) * 2001-06-15 2007-06-05 3M Innovative Properties Company Methods for the treatment of periodontal disease
JP2005501550A (en) * 2001-08-30 2005-01-20 スリーエム イノベイティブ プロパティズ カンパニー Maturation of plasmacytoid dendritic cells using immune response modifier molecules
ATE416771T1 (en) * 2001-11-16 2008-12-15 3M Innovative Properties Co N-Ä4-(4-AMINO-2-ETHYL-1H-IMIDAZOÄ4,5-CUCHINOLINE 1-YL)BUTYLUMETHANESULFONAMIDE, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF
MXPA04005023A (en) * 2001-11-29 2004-08-11 3M Innovative Properties Co Pharmaceutical formulations comprising an immune response modifier.
CA2365732A1 (en) * 2001-12-20 2003-06-20 Ibm Canada Limited-Ibm Canada Limitee Testing measurements
US6677349B1 (en) * 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
GB0204014D0 (en) * 2002-02-20 2002-04-03 Univ Surrey Improvements relating to multifilar helix antennas
NZ534566A (en) * 2002-02-22 2007-02-23 3M Innovative Properties Co Method of reducing and treating UVB-induced immunosuppression
EP1511746A2 (en) 2002-05-29 2005-03-09 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
EP1513524A4 (en) * 2002-06-07 2008-09-03 3M Innovative Properties Co Ether substituted imidazopyridines
CA2493227A1 (en) 2002-07-23 2004-01-29 Biogal Gyogyszergyar Rt. Preparation of 1h-imidazo[4,5-c]quinolin-4-amines via1h-imidazo [4,5-c]quinolin-4-phthalimide intermediates
US6841678B2 (en) 2002-07-26 2005-01-11 Biogal Gyogyszergyar Rt. Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via novel 1H-imidazo [4,5-c] quinolin-4-cyano and 1H-imidazo [4,5-c] quinolin-4-carboxamide intermediates
CA2495570C (en) 2002-08-15 2012-12-04 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
JP2006503068A (en) * 2002-09-26 2006-01-26 スリーエム イノベイティブ プロパティズ カンパニー 1H-Imidazo dimer
AU2003287324A1 (en) * 2002-12-11 2004-06-30 3M Innovative Properties Company Gene expression systems and recombinant cell lines
WO2004053452A2 (en) * 2002-12-11 2004-06-24 3M Innovative Properties Company Assays relating to toll-like receptor activity
AU2003301052A1 (en) 2002-12-20 2004-07-22 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
WO2004060319A2 (en) 2002-12-30 2004-07-22 3M Innovative Properties Company Immunostimulatory combinations
JP2006517974A (en) * 2003-02-13 2006-08-03 スリーエム イノベイティブ プロパティズ カンパニー Methods and compositions for IRM compounds and Toll-like receptor 8
US7485432B2 (en) * 2003-02-27 2009-02-03 3M Innovative Properties Company Selective modulation of TLR-mediated biological activity
US8110582B2 (en) 2003-03-04 2012-02-07 3M Innovative Properties Company Prophylactic treatment of UV-induced epidermal neoplasia
JP2006519877A (en) * 2003-03-07 2006-08-31 スリーエム イノベイティブ プロパティズ カンパニー 1-amino 1H-imidazoquinoline
US7163947B2 (en) * 2003-03-07 2007-01-16 3M Innovative Properties Company 1-Amino 1H-imidazoquinolines
AU2004220465A1 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Method of tattoo removal
AU2004220466A1 (en) * 2003-03-13 2004-09-23 3M Innovative Properties Company Methods for diagnosing skin lesions
US8426457B2 (en) * 2003-03-13 2013-04-23 Medicis Pharmaceutical Corporation Methods of improving skin quality
US20040192585A1 (en) * 2003-03-25 2004-09-30 3M Innovative Properties Company Treatment for basal cell carcinoma
US20040265351A1 (en) * 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US7923560B2 (en) * 2003-04-10 2011-04-12 3M Innovative Properties Company Delivery of immune response modifier compounds
WO2004096144A2 (en) * 2003-04-28 2004-11-11 3M Innovative Properties Company Compositions and methods for induction of opioid receptors
WO2004110992A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company Process for imidazo[4,5-c] pyridin-4-amines
WO2004110991A2 (en) * 2003-06-06 2004-12-23 3M Innovative Properties Company PROCESS FOR IMIDAZO[4,5-c]PYRIDIN-4-AMINES
US7445013B2 (en) 2003-06-17 2008-11-04 Whirlpool Corporation Multiple wash zone dishwasher
RU2006102187A (en) * 2003-07-31 2006-08-10 3М Инновейтив Пропертиз Компани (US) COMPOSITIONS FOR ENAPSULATION AND REGULATED RELEASE
CA2534313C (en) * 2003-08-05 2013-03-19 3M Innovative Properties Company Formulations containing an immune response modifier
EP1653914A4 (en) * 2003-08-12 2008-10-29 3M Innovative Properties Co Oxime substituted imidazo-containing compounds
US7799800B2 (en) * 2003-08-14 2010-09-21 3M Innovative Properties Company Lipid-modified immune response modifiers
US20050048072A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
JP2007503268A (en) * 2003-08-25 2007-02-22 スリーエム イノベイティブ プロパティズ カンパニー Delivery of immune response modifying compounds
ES2406730T3 (en) * 2003-08-27 2013-06-07 3M Innovative Properties Company Imidazoquinolines substituted with aryloxy and arylalkylenoxy
US20060216333A1 (en) * 2003-09-02 2006-09-28 Miller Richard L Methods related to the treatment of mucosal associated conditions
JP2007504269A (en) * 2003-09-05 2007-03-01 スリーエム イノベイティブ プロパティズ カンパニー Method for treating CD5 + B cell lymphoma
JP2007505629A (en) * 2003-09-17 2007-03-15 スリーエム イノベイティブ プロパティズ カンパニー Selective regulation of TLR gene expression
EP1668009A1 (en) 2003-09-26 2006-06-14 Rigel Pharmaceuticals, Inc. Hcv inhibitors and methods of using them
WO2005033049A2 (en) * 2003-10-01 2005-04-14 Taro Pharmaceuticals U.S.A., Inc. METHOD OF PREPARING 4-AMINO-1H-IMIDAZO(4,5-c)QUINOLINES AND ACID ADDITION SALTS THEREOF
US7544697B2 (en) * 2003-10-03 2009-06-09 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and analogs thereof
US8871782B2 (en) 2003-10-03 2014-10-28 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
MY146124A (en) 2003-10-03 2012-06-29 3M Innovative Properties Co Pyrazolopyridines and analogs thereof
US20090075980A1 (en) * 2003-10-03 2009-03-19 Coley Pharmaceutical Group, Inc. Pyrazolopyridines and Analogs Thereof
AU2004285575A1 (en) * 2003-10-31 2005-05-12 3M Innovative Properties Company Neutrophil activation by immune response modifier compounds
EP1685129A4 (en) * 2003-11-14 2008-10-22 3M Innovative Properties Co Oxime substituted imidazo ring compounds
CA2545825A1 (en) 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
WO2005051317A2 (en) * 2003-11-25 2005-06-09 3M Innovative Properties Company Substituted imidazo ring systems and methods
JP2007512349A (en) 2003-11-25 2007-05-17 スリーエム イノベイティブ プロパティズ カンパニー Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
US20050226878A1 (en) * 2003-12-02 2005-10-13 3M Innovative Properties Company Therapeutic combinations and methods including IRM compounds
WO2005055932A2 (en) * 2003-12-02 2005-06-23 3M Innovative Properties Company Therapeutic combinations and methods including irm compounds
CA2549216A1 (en) * 2003-12-04 2005-08-25 3M Innovative Properties Company Sulfone substituted imidazo ring ethers
WO2005066170A1 (en) * 2003-12-29 2005-07-21 3M Innovative Properties Company Arylalkenyl and arylalkynyl substituted imidazoquinolines
CN1922178A (en) * 2003-12-29 2007-02-28 3M创新有限公司 Piperazine, [1,4]diazepane, [1,4]diazocane, and [1,5]diazocane fused imidazo ring compounds
US8735421B2 (en) * 2003-12-30 2014-05-27 3M Innovative Properties Company Imidazoquinolinyl sulfonamides
JP2007517055A (en) * 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー Enhanced immune response
US20050201959A1 (en) * 2004-03-11 2005-09-15 Vvii Newco 2003, Inc. Methods and compositions for altering skin coloration
AU2005222995B2 (en) 2004-03-15 2010-08-26 3M Innovative Properties Company Immune response modifier formulations and methods
US8697873B2 (en) * 2004-03-24 2014-04-15 3M Innovative Properties Company Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
JP2007532572A (en) * 2004-04-09 2007-11-15 スリーエム イノベイティブ プロパティズ カンパニー Methods, compositions and preparations for delivering immune response modifiers
WO2006126981A2 (en) * 2004-04-28 2006-11-30 3M Innovative Properties Company Compositions and methods for mucosal vaccination
US20050267145A1 (en) * 2004-05-28 2005-12-01 Merrill Bryon A Treatment for lung cancer
US7569580B2 (en) 2004-06-03 2009-08-04 Rigel Pharmaceuticals, Inc. Heterotricyclic compounds for use as HCV inhibitors
US20080015184A1 (en) * 2004-06-14 2008-01-17 3M Innovative Properties Company Urea Substituted Imidazopyridines, Imidazoquinolines, and Imidazonaphthyridines
US8017779B2 (en) * 2004-06-15 2011-09-13 3M Innovative Properties Company Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
WO2006009826A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
JP5128940B2 (en) * 2004-06-18 2013-01-23 スリーエム イノベイティブ プロパティズ カンパニー Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
WO2006065280A2 (en) * 2004-06-18 2006-06-22 3M Innovative Properties Company Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods
US7897609B2 (en) * 2004-06-18 2011-03-01 3M Innovative Properties Company Aryl substituted imidazonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
ITMI20041282A1 (en) * 2004-06-24 2004-09-24 Dipharma Spa IMIQUIMOD PREPARATION PROCEDURE
US20060045886A1 (en) * 2004-08-27 2006-03-02 Kedl Ross M HIV immunostimulatory compositions
AU2005282523A1 (en) 2004-09-02 2006-03-16 3M Innovative Properties Company 2-amino 1H imidazo ring systems and methods
WO2006028962A2 (en) * 2004-09-02 2006-03-16 3M Innovative Properties Company 1-alkoxy 1h-imidazo ring systems and methods
US20090270443A1 (en) * 2004-09-02 2009-10-29 Doris Stoermer 1-amino imidazo-containing compounds and methods
US20080193468A1 (en) * 2004-09-08 2008-08-14 Children's Medical Center Corporation Method for Stimulating the Immune Response of Newborns
WO2006042254A2 (en) * 2004-10-08 2006-04-20 3M Innovative Properties Company Adjuvant for dna vaccines
US20110070575A1 (en) * 2004-12-08 2011-03-24 Coley Pharmaceutical Group, Inc. Immunomodulatory Compositions, Combinations and Methods
US7943609B2 (en) * 2004-12-30 2011-05-17 3M Innovative Proprerties Company Chiral fused [1,2]imidazo[4,5-C] ring compounds
ES2538498T3 (en) * 2004-12-30 2015-06-22 Meda Ab Use of Imiquimod for the treatment of skin metastases from a breast cancer tumor
US8436176B2 (en) * 2004-12-30 2013-05-07 Medicis Pharmaceutical Corporation Process for preparing 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine
KR20070107685A (en) * 2004-12-30 2007-11-07 다케다 야쿠힌 고교 가부시키가이샤 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate and 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine methanesulfonate
AU2005326708C1 (en) 2004-12-30 2012-08-30 3M Innovative Properties Company Substituted chiral fused [1,2]imidazo[4,5-c] ring compounds
AU2006210392A1 (en) * 2005-02-04 2006-08-10 Coley Pharmaceutical Group, Inc. Aqueous gel formulations containing immune response modifiers
WO2006086449A2 (en) * 2005-02-09 2006-08-17 Coley Pharmaceutical Group, Inc. Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines
US8378102B2 (en) 2005-02-09 2013-02-19 3M Innovative Properties Company Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods
US7968563B2 (en) 2005-02-11 2011-06-28 3M Innovative Properties Company Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
WO2006091394A2 (en) * 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
EP1851224A2 (en) * 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinolines
WO2006091568A2 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
JP2008538203A (en) * 2005-02-23 2008-10-16 コーリー ファーマシューティカル グループ，インコーポレイテッド A method for preferentially inducing biosynthesis of interferon
EP1851218A2 (en) * 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
MX2007011112A (en) 2005-03-14 2007-11-07 Graceway Pharmaceuticals Llc Method of treating actinic keratosis.
BRPI0609399A2 (en) * 2005-03-21 2010-03-30 Ferrer Int method for producing 1-substituted 1h-imidazo [4,5-c] quinolin-4-amine compounds and intermediates thereof
US7943610B2 (en) 2005-04-01 2011-05-17 3M Innovative Properties Company Pyrazolopyridine-1,4-diamines and analogs thereof
JP2008538550A (en) 2005-04-01 2008-10-30 コーリー ファーマシューティカル グループ，インコーポレイテッド 1-Substituted pyrazolo (3,4-c) cyclic compounds as modulators of cytokine biosynthesis for treating viral infections and neoplastic diseases
AU2006241166A1 (en) * 2005-04-25 2006-11-02 3M Innovative Properties Company Immunostimulatory compositions
BRPI0615788A2 (en) * 2005-09-09 2011-05-24 Coley Pharm Group Inc n- {2- [4-amino (ethoxymethyl) -1h-imidazo [4,5-c] quinolin-1-yl] -1,1-dimethylethyl} methanesulfonamide amide and carbamate derivatives, pharmaceutical composition of these and their uses
ZA200803029B (en) * 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
US20070081962A1 (en) * 2005-10-06 2007-04-12 Amit Munshi Novel delivery of immune response modifiers for removal of chronic tattoos
JP5247458B2 (en) 2005-11-04 2013-07-24 スリーエム・イノベイティブ・プロパティーズ・カンパニー Hydroxy and alkoxy substituted 1H-imidazoquinolines and methods
WO2007100634A2 (en) 2006-02-22 2007-09-07 3M Innovative Properties Company Immune response modifier conjugates
US8329721B2 (en) * 2006-03-15 2012-12-11 3M Innovative Properties Company Hydroxy and alkoxy substituted 1H-imidazonaphthyridines and methods
WO2008008432A2 (en) * 2006-07-12 2008-01-17 Coley Pharmaceutical Group, Inc. Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
US8178539B2 (en) * 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
US20080149123A1 (en) 2006-12-22 2008-06-26 Mckay William D Particulate material dispensing hairbrush with combination bristles
EP2009002A1 (en) * 2007-06-21 2008-12-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems
US20110033515A1 (en) * 2009-08-04 2011-02-10 Rst Implanted Cell Technology Tissue contacting material
JP2013534248A (en) 2010-08-17 2013-09-02 スリーエム イノベイティブ プロパティズ カンパニー Compositions, formulations and methods of lipidated immune response modulating compounds
EP3153180A1 (en) 2011-06-03 2017-04-12 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
CN103582496B (en) 2011-06-03 2016-05-11 3M创新有限公司 There is the Heterobifunctional connection base of polyethylene glycol segment and the immune response modifier conjugate of being made by it
US20130023736A1 (en) 2011-07-21 2013-01-24 Stanley Dale Harpstead Systems for drug delivery and monitoring
EP2844282B1 (en) 2012-05-04 2019-06-12 Pfizer Inc Prostate-associated antigens and vaccine-based immunotherapy regimens
US11306083B2 (en) 2017-12-20 2022-04-19 3M Innovative Properties Company Amide substituted imidazo[4,5-C]quinoline compounds with a branched chain linking group for use as an immune response modifier

Citations (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764681A (en) 1970-07-08 1973-10-09 Lilly Co Eli Certain tetrazolo-(1,5-a) quinoline compounds as fungus control agents
US3891653A (en) 1970-07-08 1975-06-24 Lilly Co Eli Substituted 4-5 dehydro-tetrazolo(1,5-a)quinolenes
US4689338A (en) 1983-11-18 1987-08-25 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
US4698348A (en) 1983-11-18 1987-10-06 Riker Laboratories, Inc. 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
EP0385630A2 (en) 1989-02-27 1990-09-05 Riker Laboratories, Inc. 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
WO1994017043A1 (en) 1993-01-29 1994-08-04 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5367076A (en) 1990-10-05 1994-11-22 Minnesota Mining And Manufacturing Company Process for imidazo[4,5-C]quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3314941A (en) 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
US5035420A (en) * 1988-11-28 1991-07-30 Therabite Corporation Jaw exerciser
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US5037986A (en) 1989-03-23 1991-08-06 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo[4,5-c]quinolin-4-amines
NZ232740A (en) 1989-04-20 1992-06-25 Riker Laboratories Inc Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
CA2167042A1 (en) 1993-07-15 1995-01-26 Kyle J. Lindstrom Imidazo[4,5-c]pyridin-4-amines
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US5684799A (en) * 1995-03-28 1997-11-04 Bell Atlantic Network Services, Inc. Full service network having distributed architecture
US5544161A (en) * 1995-03-28 1996-08-06 Bell Atlantic Network Services, Inc. ATM packet demultiplexer for use in full service network having distributed architecture
JPH09208584A (en) 1996-01-29 1997-08-12 Terumo Corp Amide derivative, pharmaceutical preparation containing the same, and intermediate for synthesizing the same
JPH09255926A (en) 1996-03-26 1997-09-30 Diatex Co Ltd Pressure-sensitive tape
US6021158A (en) * 1996-05-09 2000-02-01 Texas Instruments Incorporated Hybrid wireless wire-line network integration and management
ES2290969T3 (en) 1996-10-25 2008-02-16 Minnesota Mining And Manufacturing Company AMENDING COMPOUNDS OF THE IMMUNE RESPONSE FOR THE TREATMENT OF DISEASES MEDIATED BY TH2 AND RELATED.
US5939090A (en) 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
WO1998030562A1 (en) 1997-01-09 1998-07-16 Terumo Kabushiki Kaisha Novel amide derivatives and intermediates for the synthesis thereof
UA67760C2 (en) 1997-12-11 2004-07-15 Міннесота Майнінг Енд Мануфакчурінг Компані Imidazonaphthyridines and use thereof to induce the biosynthesis of cytokines
JPH11222432A (en) 1998-02-03 1999-08-17 Terumo Corp Preparation for external use containing amide derivative inducing interferon
JPH11255926A (en) 1998-03-13 1999-09-21 Toray Ind Inc Silicone molding and its production
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
JP2000119271A (en) 1998-08-12 2000-04-25 Hokuriku Seiyaku Co Ltd 1h-imidazopyridine derivative
KR20010101420A (en) 1999-01-08 2001-11-14 캐롤린 에이. 베이츠 Formulations and Methods for Treatment of Mucosal Associated Conditions With an Immune Response Modifier
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
JP2000247884A (en) 1999-03-01 2000-09-12 Sumitomo Pharmaceut Co Ltd Arachidonic acid-induced skin disease-treating agent
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US6451810B1 (en) 1999-06-10 2002-09-17 3M Innovative Properties Company Amide substituted imidazoquinolines
US6541485B1 (en) 1999-06-10 2003-04-01 3M Innovative Properties Company Urea substituted imidazoquinolines
US6376669B1 (en) 1999-11-05 2002-04-23 3M Innovative Properties Company Dye labeled imidazoquinoline compounds
US6894060B2 (en) 2000-03-30 2005-05-17 3M Innovative Properties Company Method for the treatment of dermal lesions caused by envenomation
US20020055517A1 (en) 2000-09-15 2002-05-09 3M Innovative Properties Company Methods for delaying recurrence of herpes virus symptoms
JP2002145777A (en) 2000-11-06 2002-05-22 Sumitomo Pharmaceut Co Ltd Therapeutic agent for arachidonic acid-induced dermatosis
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
JP2005500510A (en) 2000-12-08 2005-01-06 スリーエム イノベイティブ プロパティズ カンパニー A screening method to identify compounds that selectively induce interferon alpha
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6525064B1 (en) 2000-12-08 2003-02-25 3M Innovative Properties Company Sulfonamido substituted imidazopyridines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
UA74593C2 (en) 2000-12-08 2006-01-16 3M Innovative Properties Co Substituted imidazopyridines
EP1401437A1 (en) 2001-06-15 2004-03-31 3M Innovative Properties Company Immune response modifiers for the treatment of periodontal disease

Patent Citations (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3891653A (en) 1970-07-08 1975-06-24 Lilly Co Eli Substituted 4-5 dehydro-tetrazolo(1,5-a)quinolenes
US3764681A (en) 1970-07-08 1973-10-09 Lilly Co Eli Certain tetrazolo-(1,5-a) quinoline compounds as fungus control agents
US4689338A (en) 1983-11-18 1987-08-25 Riker Laboratories, Inc. 1H-Imidazo[4,5-c]quinolin-4-amines and antiviral use
US4698348A (en) 1983-11-18 1987-10-06 Riker Laboratories, Inc. 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents
US5756747A (en) 1989-02-27 1998-05-26 Riker Laboratories, Inc. 1H-imidazo 4,5-c!quinolin-4-amines
EP0385630A2 (en) 1989-02-27 1990-09-05 Riker Laboratories, Inc. 1H-imidazo(4,5-c)Quinolin-4-amines as antivirals
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
US5602256A (en) 1989-10-26 1997-02-11 Riker Laboratories, Inc. Process for 1H-imidazo[4,5-C]quinolines
US5578727A (en) 1989-10-26 1996-11-26 Riker Laboratories, Inc. Process for 1H-imidazo[4,5-c]quinolines
US5367076A (en) 1990-10-05 1994-11-22 Minnesota Mining And Manufacturing Company Process for imidazo[4,5-C]quinolin-4-amines
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5605899A (en) 1991-03-01 1997-02-25 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5525612A (en) 1991-09-04 1996-06-11 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo-[4,5-c]quinolin-4-amines
US5346905A (en) 1991-09-04 1994-09-13 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo-[4,5-C]quinolin-4-amines
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5714608A (en) 1991-09-04 1998-02-03 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo- 4,5-c!quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
WO1994017043A1 (en) 1993-01-29 1994-08-04 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5693811A (en) 1996-06-21 1997-12-02 Minnesota Mining And Manufacturing Company Process for preparing tetrahdroimidazoquinolinamines
US5741908A (en) 1996-06-21 1998-04-21 Minnesota Mining And Manufacturing Company Process for reparing imidazoquinolinamines

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Chemistry of Heterocyclic Compounds (English Edition) 1981, 16, (12), 1286-1288 (Zyryanov).
J. Prakt. Chem., 336 (1994), 311-318 (Steinschifter).

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090324551A1 (en) * 2005-08-22 2009-12-31 The Regents Of The University Of California Office Of Technology Transfer Tlr agonists
US9359360B2 (en) 2005-08-22 2016-06-07 The Regents Of The University Of California TLR agonists
US20070100146A1 (en) * 2005-11-03 2007-05-03 Trevor Dzwiniel Process for the preparation of imidazo[4,5-c]-quinolin-4-amines
US8846697B2 (en) 2006-05-31 2014-09-30 The Regents Of The University Of California Purine analogs
US9050376B2 (en) 2007-02-07 2015-06-09 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US8357374B2 (en) 2007-02-07 2013-01-22 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US8790655B2 (en) 2007-02-07 2014-07-29 The Regents Of The University Of California Conjugates of synthetic TLR agonists and uses therefor
US20090202626A1 (en) * 2008-02-07 2009-08-13 Carson Dennis A Treatment of bladder diseases with a tlr7 activator
US9066940B2 (en) 2009-02-06 2015-06-30 Telormedix, Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US9107919B2 (en) 2009-02-06 2015-08-18 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
US8729088B2 (en) 2009-02-11 2014-05-20 The Regents Of The University Of California Toll-like receptor modulators and treatment of diseases
US20100210598A1 (en) * 2009-02-11 2010-08-19 Regents Of The University Of California, San Diego Toll-like receptor modulators and treatment of diseases
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms

Also Published As

Publication number Publication date
NO316564B1 (en) 2004-02-23
NO986002D0 (en) 1998-12-18
IL127348A0 (en) 1999-10-28
US7026482B2 (en) 2006-04-11
IL148318A (en) 2007-05-15
US6613902B2 (en) 2003-09-02
US5741908A (en) 1998-04-21
PT912565E (en) 2004-08-31
NO20032133L (en) 1998-12-18
JP4139915B2 (en) 2008-08-27
US5998619A (en) 1999-12-07
DK0912565T3 (en) 2004-08-09
NO318095B1 (en) 2005-01-31
US6534654B2 (en) 2003-03-18
US6897314B2 (en) 2005-05-24
US20040019213A1 (en) 2004-01-29
CA2257846A1 (en) 1997-12-24
IL127348A (en) 2004-07-25
IL148318A0 (en) 2002-09-12
US20020188127A1 (en) 2002-12-12
NO986002L (en) 1998-12-18
IL152039A0 (en) 2003-05-29
AU3956597A (en) 1998-01-07
NO318213B1 (en) 2005-02-21
NO20032132D0 (en) 2003-05-12
US20030153762A1 (en) 2003-08-14
NO20032133D0 (en) 2003-05-12
US20030130516A1 (en) 2003-07-10
ATE264326T1 (en) 2004-04-15
NO20032134D0 (en) 2003-05-12
WO1997048704A1 (en) 1997-12-24
EP0912565B1 (en) 2004-04-14
KR20040029475A (en) 2004-04-06
IL152039A (en) 2006-08-01
JP2000512995A (en) 2000-10-03
NO318094B1 (en) 2005-01-31
DE69632207T2 (en) 2005-04-21
NO20032132L (en) 1998-12-18
KR20040029477A (en) 2004-04-06
NZ333169A (en) 2000-08-25
EP0912565A1 (en) 1999-05-06
US6624305B2 (en) 2003-09-23
US6150523A (en) 2000-11-21
NO20032134L (en) 1998-12-18
AU721036B2 (en) 2000-06-22
US20050096470A1 (en) 2005-05-05
KR20040029476A (en) 2004-04-06
CA2257846C (en) 2007-09-11
DE69632207D1 (en) 2004-05-19
ES2215203T3 (en) 2004-10-01

Similar Documents

Publication Publication Date Title
US6437131B1 (en) Process for preparing imidazoquinolinamines
EP0912564B1 (en) Process for preparing tetrahydroimidazoquinolinamines
AU677381B2 (en) Process for preparing quinoline amines
KR100459583B1 (en) Manufacturing method of imidazoquinolineamines
KR100457473B1 (en) Method for producing tetrahydroimidazoquinolinamine
IL152040A (en) 4 - triphenylphosphinylamino - 1h - imidazo [4,5-c] quinolines, their preparation and use as intermediates in processes for preparing 1h - imidazo [4,5-c] quinolin - 4 - amines

Legal Events

Date Code Title Description
AS Assignment

Owner name: 3M INNOVATIVE PROPERTIES COMPANY, MINNESOTA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MINNESOTA MINING AND MANUFACTURING, A CORPORATION OF DELAWARE;REEL/FRAME:011382/0130

Effective date: 20001003

STCF Information on status: patent grant

Free format text: PATENTED CASE

CC Certificate of correction
CC Certificate of correction
FPAY Fee payment

Year of fee payment: 4

AS Assignment

Owner name: GRACEWAY PHARMACEUTICALS, LLC, TENNESSEE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:3M INNOVATIVE PROPERTIES COMPANY;REEL/FRAME:018866/0444

Effective date: 20061229

AS Assignment

Owner name: BANK OF AMERICA, N.A., AS FIRST LIEN COLLATERAL AG

Free format text: FIRST LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS;ASSIGNORS:GRACEWAY PHARMACEUTICALS, LLC;CHESTER VALLEY PHARMACEUTICALS, LLC;REEL/FRAME:019035/0859

Effective date: 20061229

AS Assignment

Owner name: BANK OF AMERICA, N.A., AS SECOND LIEN COLLATERAL A

Free format text: SECOND LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS;ASSIGNORS:GRACEWAY PHARMACEUTICALS, LLC;CHESTER VALLEY PHARMACEUTICALS, LLC;REEL/FRAME:019055/0032

Effective date: 20061229

AS Assignment

Owner name: GRACEWAY PHARMACEUTICALS, LLC, TENNESSEE

Free format text: RELEASE OF SECOND LIEN SECURITY AGREEMENT IN PATENTS;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:019265/0704

Effective date: 20070503

Owner name: CHESTER VALLEY PHARMACEUTICALS, LLC, PENNSYLVANIA

Free format text: RELEASE OF FIRST LIEN SECURITY AGREEMENT IN PATENTS;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:019265/0696

Effective date: 20070503

Owner name: BANK OF AMERICA, N.A., AS FIRST LIEN COLLATERAL AG

Free format text: FIRST LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS;ASSIGNORS:GRACEWAY PHARMACEUTICALS, LLC;CHESTER VALLEY PHARMACEUTICALS, LLC;REEL/FRAME:019265/0712

Effective date: 20070503

Owner name: CHESTER VALLEY PHARMACEUTICALS, LLC, PENNSYLVANIA

Free format text: RELEASE OF SECOND LIEN SECURITY AGREEMENT IN PATENTS;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:019265/0704

Effective date: 20070503

Owner name: GRACEWAY PHARMACEUTICALS, LLC, TENNESSEE

Free format text: RELEASE OF FIRST LIEN SECURITY AGREEMENT IN PATENTS;ASSIGNOR:BANK OF AMERICA, N.A.;REEL/FRAME:019265/0696

Effective date: 20070503

AS Assignment

Owner name: DEUTSCHE BANK TRUST COMPANY AMERICAS, AS SECOND LI

Free format text: SECOND LIEN GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS AND TRADEMARKS;ASSIGNORS:GRACEWAY PHARMACEUTICALS, LLC;CHESTER VALLEY PHARMACEUTICALS, LLC;REEL/FRAME:019280/0054

Effective date: 20070503

FPAY Fee payment

Year of fee payment: 8

AS Assignment

Owner name: MEDICIS PHARMACEUTICAL CORPORATION, ARIZONA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:GRACEWAY PHARMACEUTICALS, LLC;REEL/FRAME:027370/0813

Effective date: 20111202

AS Assignment

Owner name: GOLDMAN SACHS LENDING PARTNERS LLC, NEW YORK

Free format text: SECURITY AGREEMENT;ASSIGNOR:MEDICIS PHARMACEUTICAL CORPORATION;REEL/FRAME:030281/0433

Effective date: 20130423

FPAY Fee payment

Year of fee payment: 12

AS Assignment

Owner name: BARCLAYS BANK PLC, AS SUCCESSOR AGENT, NEW YORK

Free format text: NOTICE OF SUCCESSION OF AGENCY;ASSIGNOR:GOLDMAN SACHS LENDING PARTNERS, LLC;REEL/FRAME:034749/0689

Effective date: 20150108